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T cells are CD4 lymphocytes that are further divided into subclasses such as T 
helper (Th)1, Th2, and Th17. These cells participate in cell-mediated immunity 
and play a role in autoimmune diseases. Regulatory CD4+ T cells marked for 
example by forkhead box P3 (FOXP3), contribute to maintenance of tolerance 
and regulation of immune responses. This doctoral thesis concerns the role 
of IL-17 immunity in Crohn's disease, ulcerative colitis, celiac disease, and type 
1 diabetes. 
Increased levels of mucosal IL-17 occurred in active Crohn's disease and in 
remission. In addition, FOXP3 showed elevation. The same phenomenon 
existed in Crohn's disease patients receiving TNF-α-blocking treatment, 
although the treatment had a beneficial effect on the balance of intestinal 
effector and regulatory T cells. Increased mucosal IL-17 occurred also in 
pediatric Crohn's disease and ulcerative colitis. In untreated celiac disease, 
activation of the IL-17 type of immunity and of regulatory T cells appeared. 
In children with type 1 diabetes, we found no evidence of upregulated IL-17 
immunity.
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Abstract 
Veera Hölttä. Mucosal IL-17 immunity in disease – with special reference to in-
flammatory bowel disease. National Institute for Health and Welfare (THL). Re-
search 94/2012. 135 pages. Helsinki, Finland 2012. 
ISBN 978-952-245-755-4 (printed); ISBN 978-952-245-756-1 (pdf) 
 
T cells are CD4 lymphocytes participating in cell-mediated immunity, and play a 
critical role in immune-mediated diseases. T cells divide further into subclasses such 
as Th1, Th2, and Th17 that participate in mucosal immunity responses caused by 
extracellular pathogens and also play a role in autoimmune diseases. Th17 cells 
produce cytokines called the interleukin-17 family (IL-17). Regulatory CD4+ T cells 
marked by CD4, CD25, and forkhead box P3 (FOXP3), contribute to maintaining 
tolerance and regulating immune responses to antigens. This doctoral thesis studies 
the role of IL-17 type of immunity in intestinal inflammation in Crohn’s disease, 
ulcerative colitis, celiac disease, and type I diabetes (T1D). In particular, the study 
explores the balance between effector and regulatory T cells in active and inactive 
Crohn’s disease in adults, as well as in pediatric patients with Crohn’s disease and 
ulcerative colitis. Furthermore, the investigation focuses on the effect of anti-TNF-α 
treatment on the effector and regulatory T cells in Crohn’s disease in adults. 
Adult patients with Crohn’s disease had higher numbers of intestinal IL-17+ and 
FOXP3+ cells than did control subjects, both before and after the anti-TNF-α treat-
ment. Intestinal interferon-γ and IL-17 mRNA expression was higher in Crohn’s 
disease and remained elevated after anti-TNF-α treatment, although the treatment 
improved intestinal balance between IL-17+ effector and regulatory T cells. In 
Crohn’s disease, mRNA expression of IL-17A, IL-6, and FOXP3 was increased. 
Fecal IL-17 concentration showed increase in patients with active disease. IL-17 
enhanced the IL-8 and TNF-α response of the epithelial cell line to lipopolysaccha-
ride in vitro. The findings suggest that activation of the IL-17 axis is fundamentally 
connected to the etiology of Crohn’s disease and may represent the basis for the 
relapsing nature of the disease. 
In pediatric patients, IL-17, IL-22, IL-6, and FOXP3+ mRNA up-regulation and 
increase in the number of IL-17+ and FOXP3+ cells existed in inflammatory bowel 
disease. Activation of the IL-17/IL-22 axis and up-regulation of FOXP3 occurred 
both in pediatric Crohn’s disease and ulcerative colitis, indicating shared immuno-
logical aberrancy.  
In pediatric patients with untreated celiac disease, the mucosal expression of IL-
17 and FOXP3 transcripts were elevated as compared with TGA-negative reference 
children, children with potential celiac disease, gluten-free diet-treated children with 
celiac disease, or children with T1D. Enhanced spontaneous secretion of IL-1β, IL-6, 
and IL-17 occurred in biopsy specimens from patients with untreated celiac disease. 
Activation of anti-apoptotic bcl-2 in IL-17-treated CaCo-2 epithelial cells suggests 
 
 
THL — Research 94/2012 10 Mucosal IL-17 immunity  
in disease 
 
that IL-17 might be involved in mucosal protection. Up-regulation of IL-17, howev-
er, could serve as a biomarker for the development of villous atrophy and active 
celiac disease. 
 
 
Keywords: interleukin-17, regulatory T cells, inflammatory bowel disease, celiac 
disease, type 1 diabetes 
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Tiivistelmä 
Veera Hölttä. Mucosal IL-17 immunity in disease – with special reference to in-
flammatory bowel disease [Limakalvon IL-17-immuniteetti tautitiloissa – erityis-
esti tulehduksellisessa suolistosairaudessa]. Terveyden ja hyvinvoinnin laitos (THL). 
Tutkimus 94/2012. 135 sivua. Helsinki, Finland 2012. 
ISBN 978-952-245-755-4 (painettu); ISBN 978-952-245-756-1 (pdf) 
 
CD4-lymfosyytit ovat T-soluja, jotka osaltaan toteuttavat soluvälitteistä immuniteet-
tia ja joilla on tärkeä rooli immuunivälitteisissä taudeissa. T-solut jaetaan alaluok-
kiin, kuten Th1, Th2 ja Th17, jotka osallistuvat solunulkoisten patogeenien aiheut-
tamaan immuunivasteeseen ja niillä on merkitystä autoimmuunitaudeissa. Th17-
solut tuottavat sytokiinejä, kuten interleukiini 17:ää (IL-17). Säätelevät T-solut, 
joiden merkkiaineita ovat CD4, CD25 ja FOXP3, osaltaan ylläpitävät toleranssia ja 
säätelevät immuunivastetta.  
Tässä väitöskirjatyössä tutkittiin IL-17-immuniteettia Crohnin taudissa, ulseratii-
visessa koliitissa, keliakiassa ja tyypin I diabeteksessa (T1D). Tasapainoa efektori- 
ja säätelevien T-solujen välillä selvitettiin aikuisten aktiivisessa ja inaktiivisessa 
Crohnin taudissa sekä lasten tulehduksellisissa suolistosairauksissa. Lisäksi tutkittiin 
TNF-α-salpaajahoidon vaikutusta efektorisoluihin ja sääteleviin T-soluihin aikuisten 
Crohnin taudissa. 
Crohnin tautia sairastavien aikuisten suolistosta löytyi verrokkeja enemmän IL-
17- ja FOXP3-positiivisia soluja, myös TNF-α-salpaajahoidon jälkeen. Myös suolis-
ton interferoni-γ:n ja IL-17:n lähetti-RNA-pitoisuudet olivat korkeampia kuin ver-
rokkipotilailla. Ne pysyivät korkeina huolimatta TNF-α-salpaajahoidosta, vaikka 
hoito paransi tasapainoa IL-17-positiivisten efektorisolujen ja säätelevien T-solujen 
välillä. Aktiivisessa ja remissiossa olevassa Crohnin taudissa IL-17A:n, IL-6:n ja 
FOXP3:n lähetti-RNA-pitoisuudet olivat kohonneet. In vitro IL-17 vahvisti IL-8:n ja 
TNF-α:n vastetta lipopolysakkarideille epiteelisoiluissa. Tämän vuoksi on mahdol-
lista, että IL-17-akselin aktivoituminen liittyy Crohnin taudin etiologiaan ja saattaa 
olla syy taudin relapsointitaipumukseen.  
Tulehduksellista suolistosairautta sairastavilla lapsilla todettiin IL-17:n, IL-22:n, 
IL-6:n ja FOXP3:n lähetti-RNA-tasot verrokkeja korkeammiksi. Sekä Crohnin tau-
dissa että ulseratiivisessa koliitissa oli IL-17/IL-22-akseli aktivoitunut ja FOXP3 
lisääntynyt, viitaten taudeille yhteiseen immunologiseen puutteeseen. 
Hoitamatonta keliakiaa sairastavien lasten suolen limakalvolla IL-17 ja FOXP3 
ekspressoituivat voimakkaammin verrattaessa määrää antitransglutaminaasi vasta-
ainenegatiivisiin, potentiaalista keliakiaa sairastaviin ja gluteiinittomalla dieetillä 
hoidettuihin lapsiin, tai lapsiin, joilla oli T1D. Hoitamatonta keliakiaa sairastavien 
koepaloissa oli myös enemmän spontaania IL-1β-, IL-6- ja IL-17-eritystä. IL-17:llä 
käsitellyissä CaCo-2-epiteelisoluissa aktivoitui anti-apoptoottinen bcl-2 viitaten 
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siihen, että IL-17 saattaa liittyä limakalvon suojaamiseen. IL-17:n lisääntyminen 
voisi kuitenkin toimia villusatrofian kehittymisen ja aktiivisen keliakian merkkinä. 
 
 
Avainsanat: interleukiini-17, säätelevät T-solut, tulehduksellinen suolistosairaus, 
keliakia, tyypin 1 diabetes 
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1 Introduction 
The immune system acts to protect the body from invading microbes and foreign 
antigens, but when the immune systems functions improperly the immune diseases 
arise. These diseases can be divided into: 
 
• Systemic autoimmune diseases in which symptoms occur in many organs 
and often circulating autoantibodies are markers of disease, as in systemic 
lupus erythematous and rheumatoid arthritis.  
• Tissue-specific autoimmune diseases are restricted to a single organ, as in 
celiac disease and type 1 diabetes (T1D). 
• Immune diseases or “auto-inflammatory diseases”: Inflammatory bowel 
disease, for example, in which no autoantigen specific immune response is 
detectable, but a chronic inflammatory response is maintained and results in 
self-tissue destruction. A hereditary predisposition associates with innate 
immunity, as genome-wide association studies show (NOD, CTLA-4).  
 
Autoimmune diseases comprise a group of diseases in which an unusually strong 
attack towards self-antigens causes a disease. In autoimmune diseases, typically the 
levels of symptoms vary, and symptoms occur in phases in which active and remis-
sion periods follow. The equilibrium of the immune system varies based on the 
changes in regulatory and effector mechanisms. Often inflammation turns out to be 
the trigger point of the active phase of disease. Accumulating evidence suggests that 
environmental factors play an important role in the everlasting game between the 
perpetuating homeostasis and its breakdown. A genetic predisposition exposes, 
however, individuals to development of this disease. In a rising number of cases, this 
harmful process is ongoing. To those affected, the consequences of these diseases, 
like Crohn’s disease, ulcerative colitis (UC), T1D and celiac disease, are often disa-
bling, and – if untreated – can even be fatal. In order to develop better treatment 
options or even to postpone the beginning of the disease, better understanding of the 
immunological process behind the disease is necessary. The Th17 type of cells form 
a subclass of adaptive immune cells that plays a role in the pathogenesis of many 
autoimmune type of diseases.  
This thesis aimed to study the intestinal interleukin (IL) 17 type of cell as the 
number of IL-17-positive cells in the intestine and the number of IL-17 transcripts in 
the intestinal biopsies in Crohn’s disease, in pediatric IBD, in celiac disease, and in 
T1D. 
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2 Review of the literature 
2.1 The immune system 
The immune system consists of two parts, both playing a fundamental role in the 
immunological response: the innate and the adaptive immune systems. 
The innate immune system provides the first line of defence with a fast but lim-
ited response. It presents universal and evolutionarily ancient defence mechanisms 
as plants and animal share the same molecular modules. Innate immunity depends 
on germ-line encoded receptors (Janeway, Medzhitov 2002). Broadly defined, innate 
immunity consists of all aspects of defence mechanisms: physical barriers, a secret-
ed mucus layer, epithelial cilia, soluble proteins and bioactive molecules within the 
biological fluids (or released by activation), membrane-bound receptors, and cyto-
plasmic proteins that recognize structures in invading microbes (Chaplin 2010). 
Regarding cell lines, dendritic cells, macrophages, γδ T cells, natural killer cells 
(NK), natural killer T cells (NKT), mast cells, neutrophils, and eosinophils make up 
the innate immunity that comprises the nonspecific resistance mechanisms to infec-
tious non-self. In addition to this, the innate immune system may also defend against 
non-infectious noxious insults like environmental irritants (Medzhitov 2010). Innate 
lamina propria (LP) leukocytes produce several inflammatory cytokines driving 
intestinal pathology (Harrison, Maloy 2011).  
The adaptive immune system, in contrast, is the more sophisticated one: it relies 
on a specific response to a certain stimulus. Reaction is slow, but it has the capabil-
ity to offer immunological memory for future reference. Bone marrow-originated T 
and B lymphocytes comprise the human adaptive immune system. T cells possess a 
T cell receptor (TCR) to recognize their antigen. B cells use antibodies as receptors 
in order to recognize antigens (Andersen et al. 2006). Naïve B cells express immu-
noglobulins (Ig) M and D, which switch to IgG, IgA, and IgE types of surface recep-
tors in mature cells. Activated B cells proliferate and differentiate to plasma cells 
that secrete antibodies and can further differentiate into long-lived memory cells. 
Both the forms of adaptive immune system are necessary and cooperate in order to 
maintain homeostasis in the host. They have a close relation ship and are most likely 
cross-regulated, as genome-wide association studies of immune-mediated diseases 
suggest (Barrett et al. 2008). 
2.1.1 Immunological tolerance 
The function of the immune system in discriminating between self and non-self, 
simultaneously inhibiting autoimmune responses and allowing an effective response 
against microbial antigens, is the fundamental immunological dilemma. The goal of 
Review of the literature 
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an adequate immune response is to fight external threats - pathogens and environ-
mental challenges - without damaging self-tissues (Chaplin 2010). In order to per-
form these actions, the immune system has developed various mechanisms to estab-
lish and sustain unresponsiveness to self-antigens; such unresponsiveness is called 
immunological self-tolerance. Central and peripheral tolerances work to maintain 
immunological homeostasis. Physical deletion (clonal deletion), functional inactiva-
tion (anergy), and T cell-mediated active suppression of potentially pathogenic self-
reactive T cells are the mechanisms of self-tolerance (Sakaguchi et al. 2008, Zheng, 
Rudensky 2007). Central tolerance consists of regulation of self-reactive T cell de-
velopment in the thymus (section 2.1.3). Peripheral tolerance, conversely, sustains 
homeostasis by regulating peripheral autoreactive T cells.  
2.1.2 T lymphocytes 
T lymphocytes comprise the key cell population of the adaptive immunity arm. 
Hematopoietic precursor cells originate in bone marrow and migrate to the thymus 
in order to go through a five-step maturation process (Takahama 2006):  
1. Lymphoid progenitor cells enter the thymus. 
2. At the outer cortex of the thymus, a cluster of differentiation (CD) 4+ and 
CD8+ double-positive thymocytes are generated. 
3. In the cortex occurs the positive and negative selection of double-positive 
thymocytes 
4. To complete thymocyte development, positively selected thymocytes inter-
act with medullary thymic epithelial cells. This also ensures central toler-
ance. 
5. Mature T cells exit the thymus.  
 
In order for elimination of autoreactive T cells to take place, major histocompability 
complex (MHC) classes I and II molecules present self-peptides to T cells. Some-
times this deletion process is, however, inadequate, and autoreactive T cells end up 
in the periphery. In healthy individuals, peripheral tolerance controls these autoreac-
tive cells.  
During this process, the arising T cells learn to discriminate between self and 
non-self-structures, and T cells with inappropriately high TCR affinity towards self-
peptides are deleted in a process called central tolerance (Takahama 2006). On the T 
cell, CD3 - a marker of all T cells - associates with TCR in order to transmit intra-
cellular activation signals. Expression of αβ or γδ TCR distinguishes T lymphocytes 
from other leukocytes. 
In order to become activated, T cells require a three-step pathway (Andersen et 
al. 2006):  
1. Interaction of TCR and antigen-presenting cell (APC). TCRs vary and thus 
ensure specific responses. Most of the human TCRs comprise a αβ hetero-
Review of the literature 
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dimer; some 5% of peripheral blood TCRs are γδ. In intestinal mucosa, the 
proportion of γδTCRs is higher (Aljurf et al. 2002). APCs present the anti-
genic peptides bound to the cell surface MHC. All somatic cells express 
MHC class I molecules; they present peptides originating from endogenous 
proteins. CD8+ cytotoxic T cells (CTLs) recognize these MHC I molecules. 
Only professional APCs express class II MHC molecules that present exog-
enous peptides to CD4+ T helper cells. Cytokines can, however, induce 
MCH II in the majority of cells (Andersen et al. 2006). Human leukocyte 
antigen (HLA) refers to MHC in humans, and the complex comprises three 
loci (HLA-A, -B, and –C) in chromosome six.  
2. APC gives a co-stimulatory signal to the T cell. This occurs through expres-
sion of a surface molecule B7-1 or B7-2 (CD80 or CD86) that activates re-
ceptor CD28 on the T cell. 
3. Cytokines and other mediators induce activation. Cytokines are secreted 
proteins that contribute to the initiation and guidance of the adaptive im-
mune response (Commins et al. 2010). Cells of the innate immune system 
and of the adaptive immune system secrete these cytokines. 
2.1.3 T helper cells 
CD4+ T cells comprise the T helper (Th) class of T cells. Naïve Th cells produce 
primarily IL-2. Th cells are divided into functional subtypes according to the cyto-
kines they secrete. The classical dichotomy of T helper cells consists of Th1 and Th2 
cells, first described in the mid-1980s (Mosmann et al. 1986). Thereafter, new sub-
classes have appeared, and currently Th cells are divided into several subclasses: 
Th1, Th2, Th17, iTreg, Th3, Th9, Th22, and T follicular helper (Tfh) cells (Figure 
1).  
Most of these cell classes were first described in murine models and later in hu-
mans. Unlike in mice, however, CD4 cells producing categorically distinct Th cyto-
kine profiles seldom appear in humans, but Th cells secreting, for example, both Th1 
and Th17 cytokines occur in humans. 
Th9 presents a unique subclass of IL-9–producing Th2 cells. Transforming 
growth factor (TGF) β is central to the differentiation of Th9 cells (Commins et al. 
2010). T-follicular helper cells, on the other hand, were described initially as follicu-
lar B helper T cells after the finding that in the B cell follicle reside CD4+ T cells 
expressing the chemokine receptor CXCR5. In addition, they coexpress other sur-
face markers like programmed death-1 and inducible co-stimulator (Deenick, Ma 
2011).  
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Figure 1. T helper cell differentiation. 
2.1.4 Th1 and Th2 cells 
IL-2 is a cytokine typical of both Th1 and Th2 cells. Stimulation of T cells in the 
presence of IL-1 and IL-6 induces IL-2 secretion and expression of IL-2R on effec-
tor T cells. Binding of secreted IL-2 to the IL-2R leads to clonal T cell proliferation 
(Commins et al. 2010). IL-2-specific IL-2Rα (CD25), IL-2Rβ (CD122), and the 
common γ chain form a receptor complex through which IL-2 signals. IL-2 is also 
involved in activation of NK cells, B cells, CTLs, and macrophages, thus acting both 
in adaptive and innate immunity (Commins et al. 2010). 
Typically, Th1 –mediated immune responses arise in response to an intracellular 
pathogen presented by APC in the presence of IL-12. This immune response tends to 
localize the infectious agent at the site of inflammation and to secrete cytokines 
(interferon (IFN)-γ and tumor necrosis factor (TNF) β, but no IL-4 or IL-5) that 
promote apoptosis or induce the differentiation of cytotoxic T lymphocytes. Granu-
loma is the hallmark of the Th1 response (Kobayashi et al. 2001).  
Cytokines IL-12, IL-18, and IL-27 contribute to the Th1 type differentiation 
(Manetti et al. 1993). Interaction of IL-12 and naïve T cells causes activation of 
STAT4 that leads to expression of transcription factor T-box expressed in T cells (T-
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FOXP3+ Treg cells is reduced because of their defective differentiation in the intes-
tine (Badami et al. 2011). A previous study from our group showed no infiltration of 
FOXP3-expressing cells in the small intestinal mucosa in T1D (Tiittanen et al. 
2008), and Study IV confirms this, because no difference in the number of FOXP3+ 
cells or transcripts emerged between T1D children and the reference children (origi-
nal publication IV, Figure 1). 
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bet), a master regulator for Th1 differentiation. T-bet induces production of IFN-γ 
and IL-12R and inhibits alternative Th differentiation pathways. IL-12 is a hetero-
dimer consisting of two subunits: IL-12p35 (homologous to the soluble IL-6 recep-
tor) and IL-12p40 (shared also by IL-23, homologous to IL-6). IL-12 activities in-
clude stimulation of IFN-γ production, activation of NK cells (IL-12 activates and 
induces proliferation, cytotoxity, and cytokine production of NK cells), and prolifer-
ation of Th cells and CTLs (Commins et al. 2010). In synergy with IL-12, IL-27 
induces NK and Th cells to produce IFN-γ, leading to Th1 immune deviation. IL-27 
is a heterodimer consisting of IL-27B (EBV-induced gene B) and IL-27p28 (IL-30). 
Macrophages and DCs produce IL-27 that plays an important role in Th immunity 
(Commins et al. 2010). 
Homodimer IFN-γ is the key cytokine for cell-mediated immunity to intracellular 
pathogens and is a hallmark of Th1 type immunity (Farrar, Schreiber 1993). Inter-
ferons are a class of proteins known for their ability to interfere with viral growth, 
and IFN-γ comprises the class of type II interferons. In addition to T cells, NK cells 
and to a lesser extent macrophages produce IFN-γ, suggesting it is more like an 
interleukin than an interferon. IFN-γ plays a role in MHC I and II expression and 
stimulates APCs, mononuclear phagocytic functions, and killing by NK cells and 
neutrophils (Commins et al. 2010).  
The Th2 subunit of T cells secretes a different set of cytokines: IL-4, IL-5, and 
IL-13, but not IFN-γ. Through IgE responses, and eosinophil and mast cell activa-
tion, Th2 cells promote antiparasitic immune responses. IL-4, one determinant of 
Th2 differentiation (Seder et al. 1992), activates STAT6, which in turn promotes 
expression of transcription factor GATA-3, the master regulator for Th2 type differ-
entiation. GATA-3 has a positive effect on potentiating a Th2 type response by sup-
porting IL-4 expression, Th1 suppression, and inhibition of the Th17 type response 
(together with IL-4) (Commins et al. 2010). Excessive Th2 activation promotes 
atopy. 
2.1.5 Regulatory T cells 
Regulatory T (Treg) cells are essential in regulation of the immune response to self-
antigens, allergens, commensal microbiota, infectious agents, and tumors in order to 
maintain immunological homeostasis. A lineage specification factor for these Treg 
cells is the forkhead-winged helix transcription factor FOXP3. Thymus derived 
natural T regulatory cells (nTregs) suppress self-reactive T cells in order to prevent 
autoimmunity (Sakaguchi et al. 2006). Inducible Tregs (iTregs) arise in the periph-
ery from naïve CD4+ T cells after antigen exposure, particularly in the intestine (Sun 
et al. 2007). FOXP+CD4+ cells constitute less than 10% of peripheral CD4+ cells.  
Discovery of these regulatory cells occurred in 1995 through the finding of a 
subset of CD4+ T cells expressing CD25, which is the interleukin-2 (IL-2) receptor 
α-chain (IL-2Rα). These CD4+CD25+ cells appear to possess suppressive capability 
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(Sakaguchi et al. 1995). Treg cell development in the thymus requires IL-2 
(Thornton, Shevach 1998), as it is essential for nTreg survival in the periphery 
(Sakaguchi et al. 2006). Similarly to activated T cells, these Treg cells also display 
cytotoxic T-lymphocyte antigen 4 (CTLA4), glucocorticoid-inducible tumor necro-
sis factor receptor (GITR), IL-2 receptor β -chain (CD122), lymphocyte function-
associated antigen 1 (LFA-1/CD11a), and intercellular adhesion molecule 1 (ICAM-
1) (Read et al. 2000, Yamaguchi et al. 2011). Initially these cells were considered 
anergic and thus unable to proliferate and produce IL-2, but later studies showed 
thymus-derived CD25+CD4+ Treg cells to be an example of a distinguishable long-
lived cell subset with suppressor function (Rudensky 2011).  
These Treg cells express transcription factor FOXP3 (Fontenot et al. 2003, Hori 
et al. 2003). Foxp3 serves as the master control gene for Treg function, and muta-
tions in FOXP3 cause severe failures in the immune system, indicating the role of 
Tregs as a distinct cell line. Initially, discovery of FOXP3 was done in animal stud-
ies; the X chromosomal mutation led to severe autoimmunity in “scurfy” mice 
(Brunkow et al. 2001). In humans, loss of Treg cell function results in immuno-
dysregulation polyendocrinopathy enteropathy X-linked syndrome (IPEX), a severe 
multi-organ autoimmune and inflammation disorder (Wildin et al. 2001). The clini-
cal picture of IPEX consists of gastrointestinal disease characterized by watery diar-
rhea, autoimmune endocrinopathies involving commonly the pancreas and the thy-
roid, and dermatitis in the form of a mild eczema. Symptoms vary between patients, 
and in addition to this basic triad other autoimmune alterations exist, such as hema-
tological disorders (Blanco Quiros et al. 2009).  
Tregs suggested the performance of suppressive actions by several mechanisms: 
• Modulation of APC functions 
Activated Tregs inhibit the contact of naïve T cells to APCs by reducing the 
time for T cell–dendritic cell interactions to one-third of the time spent 
when Tregs were not present (Tadokoro et al. 2006).  
• CTLA-4-dependent mechanism 
In order to activate and proliferate, naïve T cells need co-stimulatory signals 
transferred by CD28. CTLA-4 inhibits CD28-mediated co-stimulation by 
the following mechanism: CTLA-4 and CD28 share the ligands CD80 and 
CD86, but the former has higher affinity for both. Tregs express CTLA-4 
and thus inhibit the conventional T cells (Tconv) (Yokosuka et al. 2010). 
• IL-2-dependent mechanism  
All nTregs express IL-2R but produce no IL-2 and are therefore dependent 
on exogenous IL-2. They can also prevent activation of Tconv by depriving 
IL-2 of Tconv (Thornton, Shevach 1998).  
• Extracellular ATP degradation 
Extracellularly released ATP enhances immune reactions; however, en-
zymes produced by Tregs can degrade it and thus inhibit T cell activation 
(Yip et al. 2009). 
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• TGF-β 
Numerous cell types produce TGF-β: eosinophils, monocytes, and Th cells 
(of them, primarily Treg cells). Having both stimulatory and inhibitory ef-
fects, TGF-β is a pleitropic cytokine (Sporn, Roberts 1992). It is inhibitory 
for B cells, Th cells, and CTLs. Generally, TGF-β acts to inhibit prolifera-
tion and to induce apoptosis. When expressed on Tregs, TGF- β is an im-
munosuppressive cytokine, and a TGF-β-dependent feedback loop enhances 
Treg suppression. It also affects the induction and maintenance of FOXP3 
expression, differentiation of naïve T cells into FOXP3 cells in vitro, induc-
tion of peripheral FOXP3 cells in vivo (especially in the gut), and the 
maintenance of both nTregs and iTregs (Yamaguchi et al. 2011). 
• Cytotoxic and other molecules 
The cytotoxic molecules granzyme and perforin contribute to Treg-
mediated suppression of NK and CD8+ T cell activity (Cao et al. 2007). 
• IL-10/IL-35 
Another essential immunoregulatory and anti-inflammatory cytokine is IL-
10, a homodimer produced by several cell lines: Tregs, but especially in 
humans, also monocytes and B cells. IL-10 has effects that are anti-
inflammatory and suppressive to most hematopoietic cells (Rudensky 2011). 
Among other functions, IL-10 inhibits Th1 cells from producing IFN-γ and 
Th2 cells which produce IL-4 and IL-5 (Del Prete et al. 1993). For Treg-
dependent suppression, IL-10 is especially needed in the intestinal mucosal 
along with other mucosal tissues. Intestinal T cells, regardless of their 
FOXP3-status (+/-), secrete excessive IL-10 that inhibits both the genera-
tion and proliferation of Th17 cells possessing IL-10-receptors. IL-10 also 
affects tolerogenic DCs and the differentiation of CD4+ naïve cells into IL-
10-secreting cells (Yamaguchi et al. 2011).  
 
One specific subset of Tregs is IL-10-secreting Tr1 cells (Cong et al. 2002). An-
other novel population of suppressive cells comprises Tr35 cells: FOXP3- cells that 
secrete IL-35, an immune-suppressive heterodimer composed of Epstein-Barr-
induced gene 3 (Ebi-3) encoding IL-27β and IL-12α encoding IL-12α/p35. Murine 
Treg cells lacking either IL-35 dimer have reduced ability to suppress inflammation 
(Collison et al. 2007, 2010). IL-35 leads to Treg cell proliferation and reduces Th17 
cell activity (Niedbala et al. 2007). Tregs mediate potent T cell suppression in a IL-
35- and IL-10–dependent manner, suggesting that, rather than Treg function, induc-
tion of suppression is contact-dependent (Collison et al. 2009). 
Th3 cells are regulatory T cells that secrete TGF- β abundantly (Santos et al. 
1994). These primarily gut-derived cells play a role in mucosal tolerance, and partic-
ipate in secretory IgA production (Commins et al. 2010). In addition to these, also 
CD8+ T cells, natural killer T cells, B cells, and γδ TCR-expressing T cells suppress 
effector T-cell responses (MacDonald et al. 2011).  
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Regulatory T cell-mediated suppression acts in two distinctive ways: 
1. In physiological and non-inflammatory states, suppression aims to keep T 
cells in a naïve state and serves to maintain natural self-tolerance by Treg-
dependent deprivation of activation signals from responder T cells. 
2. In inflammatory states, suppression serves to sustain local immune homeo-
stasis by Treg-mediated killing and inactivation of responder T cells and 
APCs (Yamaguchi et al. 2011). 
2.1.6 Th17 cells 
The first reports of Th17 cells date to less than 10 years ago (Harrington et al. 2005); 
vigorous studies followed, and now the role of Th17 cells in the intestinal immuno-
logical response becomes clearer: Th17 cells mediate the T-cell immune response to 
extracellular mucosal pathogens.  
IL-17-secretion characterizes Th17 cells, although these cells are also able to se-
crete other cytokines. Yao et al. (1995) were the first to describe IL-17; it shares 
amino acid identity with Herpesvirus saimiri (HSV13) and murine CTLA-8. IL-17 
induces fibroblasts to produce IL-6 and IL-8, and up-regulates expression of the 
ICAM-1. IL-17 is a family of six cytokines (IL-17A through IL-17F) (Kawaguchi et 
al. 2004). In humans, IL-17A (generally referred to as IL-17) and IL-17F play a 
pivotal role. Th17 cells, neutrophils, eosinophils, and CD8+ T cells express IL-17A 
(Kawaguchi et al. 2004). IL-17A induces stromal cells, fibroblasts, endothelium, and 
epithelium to express a variety of cytokines and chemokines: IL-6, IL-11, GM-CSF, 
CXCL8, CXCL10, and TGF-β; all participating in fibroblast activation and neutro-
phil recruitment. IL-17F shows homology to the IL-17 motif; it regulates angiogene-
sis and cytokine expression in endothelial cells (Starnes et al. 2001). Th17 cells, but 
activated basophils and mast cells as well, express IL-17F (Kawaguchi et al. 2004). 
A dichotomy between FOXP3+ Tregs and Th17 cells exists. Under inflammatory 
conditions, IL-2 and IL-1β can convert human Tregs into Th17 cells (Deknuydt et 
al. 2009). In the absence of IL-6, TGF-β also induces FOXP3 and generates iTregs. 
IL-6, however, inhibits this TGF-β-driven FOXP3 expression and in cooperation 
with TGF-β induces Th17 cells (Bettelli et al. 2007). IL-6 activates STAT3, which 
in turn potentiates activation of transcription factor retinoic acid receptor-related 
orphan receptor (ROR) γt, a master regulator for Th17 cells (Commins et al. 2010). 
RUNT-related transcription factor RUNX1 induces RORγt expression, and they co-
operate during Il17 transcription. RUNX1 has a dual role: interaction of RUNX1 
and FOXP3 is necessary for FOXP3 to inhibit Th17 differentation (Zhang et al. 
2008). 
IL-6 and TGF-β activate Th17 cells, and IL-23 develops them into mature IL-17-
secreting cells (Zhou et al. 2007). IL-23 is a heterodimer consisting of IL-12p40 and 
IL-23p19. IL-23 induces remodelling through activation of matrix metalloproteinas-
es, increased angiogenesis, and reduced CD8+ T cell infiltration (Oppmann et al. 
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2000). IL-21 is central to B cell immunity but is also involved in Th17 differentia-
tion. It shares biological activities with IL-2 and IL-15: it activates NK cells and 
promotes proliferation of B and T lymphocytes (Parrish-Novak et al. 2000).  
Th17 cells also secrete IL-22, a cytokine from the IL-10-family produced by T 
cells, mast cells, and activated NK cells (Dumoutier et al. 2000, Xie et al. 2000). 
Although Th17 cells in particular express IL-22, the immune cells are not targets of 
IL-22 due to a lack of IL-22R1, another part of the heterodimer forming the IL-22 
receptor complex. IL-22 is instead a T-cell mediator that induces innate immunity in 
tissues and has many unique functions. It primarily acts on hepatocytes and epitheli-
al cells, where it promotes antimicrobial defence, regeneration, and protection 
against damage and induces acute-phase reactants and some chemokines (Wolk et 
al. 2004). IL-22 is an ambivalent cytokine (Brand et al. 2006, Andoh et al. 2005), 
meaning that in chronic inflammatory disorders it may take either a protective or a 
pathogenic role. In the intestinal barrier, IL-22 induces the expression of protective 
defensins (Brand et al. 2006). CD4+ cells secreting IL-22 form the subclass of Th 
cell called Th22 cells that produce IL-22, but no IL-17 or IFN-γ (Duhen et al. 2009, 
Trifari et al. 2009). Studies report IL-22 expression in the mucosa in IBD, especially 
in Crohn’s disease, and in the plasma of Crohn’s disease patients (Andoh et al. 2005, 
Wolk et al. 2007). 
2.2 Gut immune system 
2.2.1 Gut structure and function 
 
Figure 2. Interaction between intestinal epithelial cells, Th1, Th17, and antigen-presenting cells 
(dendritic cells). Th17 cells secrete proinflammatory cytokines, which in turn stimulate intestinal 
epithelial cells. Bacteria act on antigen-presenting cells, supporting the secretion of IL-12, a stimulus 
for Th1 expansion, and IL-23, a stimulus for Th17 expansion. (Adapted from Hundorfean et al. 2012)  
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The gut constitutes a crucial organ for communication between the body and its 
external environment. In an adult human being, intestinal epithelium covers an area 
of 300 to 400 m2, thus comprising the largest organ communicating with various 
pathogenic and non-pathogenic micro-organisms such as infective agents, food anti-
gens, and allergens, all of them potentially provoking a harmful immune response.  
The intestinal epithelium serves as the primary protection against the external 
environment, and as the first line of defence, the epithelial and Paneth cells play an 
important role (Figure 2). The barrier against all these outsider threats is generally 
only one cell layer thick but yet protected by various chemical and physical innate 
defence mechanisms having close cooperation with the adaptive immune system 
(Turner 2009). Further, the high acidity of the stomach and active proteolytic en-
zymes secreted by the pancreas reduce the numbers of living micro-organism reach-
ing the intestine. They also effectively digest antigenic proteins to small peptides 
unable to initiate immune responses.  
A thick layer of mucus forms a physical and biological protective barrier, and 
stabilizes the antibody concentration. Intestinal villous epithelium houses goblet 
cells, which produce mucin 2, an intestinal mucus-formation molecule. In mice dele-
tion of mucin 2, a major mucin component, results in intestinal inflammation (Van 
der Sluis et al. 2006).  
Intercellular junctions between the epithelial cells called tight junctions (TJ), and 
also known as zonula occludens, regulate epithelial permeability. The TJ in epitheli-
al cells includes the integral membrane proteins (occludins), junctional adhesion 
molecules, claudin proteins, scaffold proteins (ZO-1 and myosin IXB), and zonulin 
(Turner 2009). Zonulin is a 47-kDa protein involved in intestinal immunity and 
associated with autoimmune diseases: its upregulation occurs both in celiac disease 
and in T1D (Clemente et al. 2003, Sapone et al. 2006, Fasano 2011). Upregulation 
of zonulin is also linked to other autoimmune diseases such as ankylosing spondyli-
tis, rheumatoid arthritis, and Crohn’s disease - thus linking together the diseases 
studied here.  
To cross the intestinal barrier, absorbed proteins mainly use a transcellular path-
way during which lysosomal degradation converts the proteins to nonimmunogenic 
peptides. A small amount of proteins (10%) carry on as intact proteins leading to 
antigen-specific immune responses. This process uses the microfold (M) cell or the 
paracellular pathway that regulates intercellular TJ, and antigenic tolerance follows 
(Neutra et al. 2001). The intestinal epithelium plays an active role in both the innate 
and the adaptive type of mucosal immunity through the collaboration of adjacent 
epithelial cells (ECs), parenchymal cells, hematopoietic cells, and likely microbial 
components in the lumen (Paul 2003).  
Underneath the surface epithelium and above the muscularis mucosa is LP, an 
area populated by smooth muscle cells, fibroblasts, and cells belonging to the gut-
associated lymphoid tissue (GALT), discussed below. 
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2.2.2 Cells in the gut-associated lymphoid tissue 
GALT is part of the mucosal-associated lymphoid system (MALT) and plays a ma-
jor role in the body’s delicate equilibrium. GALT consists of mesenteric lymph 
nodes, Peyer’s patches (PPs), isolated lymph nodes, T and B lymphocytes, macro-
phages, dendritic cells, mast cells, neutrophils, and other granulocytes. 
In a normal gastrointestinal (GI) tract, about one-third of the intestinal LP cells 
constitute T cells distributed into CD4+ and CD8+ T cells similarly as in peripheral 
blood. Most of these lamina propria lymphocytes (LPLs) are HLA-DR+, α4β7+, 
CD62lo, CD25hi/lo, and CR45RO+, similar to effector-memory cells (MacDonald et al. 
2011). In equal abundance to T cells are IgA-producing plasma cells, in addition to 
which, macrophages and dendritic cells (DCs) reside in the intestine (Macdonald, 
Monteleone 2005). In the small intestine, the epithelial layer contains one T cell for 
every 10 epithelial cells; in the large intestine the ratio is approximately 1:20. De-
spite the activated immune cells, healthy individuals have no pathologic features 
indicating that regulatory pathways maintain immunologic homeostasis. In inflam-
matory diseases of the intestinal tract this homeostasis is interrupted, and intestinal 
inflammation is evident. Inflammation most likely arises from homeostatic disrup-
tions and recognition of normal microbiota as pathogens (Macdonald, Monteleone 
2005). 
In addition to PPs, interactions between commensal bacteria, GI antigens, and 
immune cells take place in isolated follicles. In these follicles, M cells within the 
follicle-associated epithelium translocate antigens from the lumen. Immature mye-
loid DCs encounter and process these antigens, become differentiated into mature 
DCs, and migrate to PPs or mesenteric lymph nodes (MLNs) in order to activate T 
cells. GALT thus serves as a source of activated effector cells. Other mechanisms by 
which luminal bacteria enter the body are the M-cell-independent pathway consist-
ing of LP DCs that extend dendrites into the lumen, and the columnar epithelial cells 
that are eligible for antigen uptake (MacDonald et al. 2011).  
First, naïve T cells home to the PPs or MLNs, where they encounter antigen-
loaded DCs that prime, polarize, and expand the lymphocytes to yield Th1 or Th17-
effector cells (Yen et al. 2006). DCs present enteric antigens in association with 
MHC II. T cells proliferate during this initial priming process and enhance expres-
sion of surface molecules (such as α4β7, CCR 9, LFA-1, and CD44). Following 
initial priming, the effector T cells reenter the circulation and home to the intestinal 
interstitium. APCs present to T cells their specific antigen, resulting in a rapid and 
avid response of T cells that elevates the production of IFN-γ, IL-17, TNF-α, lym-
photoxin-α, and IL-2. The production of these cytokines further enhances the pro-
duction of Th1/Th17 and of macrophage-derived inflammatory mediators, resulting 
in recruitment and activation of additional intestinal leukocytes, thus causing intesti-
nal inflammation (Koboziev et al. 2010). In LP T cells, TCR signaling is 
hyporesponsive compared to that of peripheral blood T cells. In addition to activated 
? ? Mucosal IL-17 immunity  
???in disease 
 
Review of the literature 
 
THL — Research 94/2012 31 
 
CD4 cells, CD8 cells recognizing MHC class I molecules are also present in the LP, 
although they predominate in the epithelium.  
2.2.3 Mucosal immune response 
In the intestine, immunological tolerance is crucial; the intestinal immune system 
must defend against pathogens but at the same time coexist with resident intestinal 
microbiota. Mechanisms of tolerance include limiting intestinal microbial exposure 
and actively down-regulating the immune response (Abraham, Medzhitov 2011). 
Microbial signals affect intestinal immune tolerance, and inflammatory processes 
can be down-regulated by host-microbial interaction. These interactions may regu-
late pattern recognition receptor (PRR) expression and responsiveness, secrete inhib-
itory mediators, and modulate transcription and expression in intracellular signaling 
pathways (Abraham, Medzhitov 2011). The GI tract poorly tolerates any type of 
uncontrolled immune response, and thus intestinal inflammation easily follows 
(Siegmund, Zeitz 2011).  
In animal models, development of oral tolerance relies on bacterial colonization 
of the GI tract (Sudo et al. 1997, Tsuda et al. 2010). Unlike other tissues, the intesti-
nal mucosa experiences continuous physiologic inflammation. The intestine is ex-
posed to a huge antigenic load ranging from luminal bacteria to toll-like receptor 
(TLR) ligands and potential mitogens. Intestinal innate immunity includes the epi-
thelial barrier and phagocytic cells within the LP (macrophages, dendritic cells, and 
neutrophils). In addition, it encompasses several innate leukocyte and intestinal epi-
thelial cells (IEC) populations, which cooperate to sustain a balanced immune re-
sponse to the microbiota (Harrison, Maloy 2011). 
2.2.4 Immune regulation by commensal microbiota 
The intestinal tract houses microbial communities that are essential for mammalian 
health. These microbial communities, termed the intestinal microbiota, sustain a 
symbiosis with their host. The intestinal microbiota consist of about 1014 bacteria 
that aid the host by breaking down indigestible food, (e.g. fiber), in part into absorb-
able compounds, at the same time they secure for themselves an environment with a 
constant flow of nutrients. To maintain homeostasis, the immune system plays a 
dual role: it has to be tolerant to the microbiota but simultaneously respond efficient-
ly to infection. The microbiota itself also prevents outgrowth of pathogens, but 
changes in the complexity and density of the microbiota can disrupt this ability (Jar-
chum, Pamer 2011). A variety of factors influences the microbiota composition: 
diet, antibiotic therapy, environmental exposure to microorganisms, and sequential 
microbial colonization in the neonatal period. Production of antimicrobial peptides 
by Paneth cells, mucus production by goblet cells, and the control of microbes by 
secretory IgA are all immune defence mechanisms serving to maintain immune 
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homeostasis. Dysregulation of these host-microbe interactions can lead to intestinal 
inflammation (Abraham, Medzhitov 2011).  
The intestinal immune system defends against microbiota. PRRs recognize mi-
croorganisms and initiate defence action. TLRs, C-type lectins, nucleotide-binding 
domain and leucine-rich repeat-containing receptors, and retinoic acid-inducible 
gene 1-like receptors are PRRs that recognize pathogen-associated molecular pat-
terns. TLRs participate both in innate and in adaptive immune responses and play a 
key role in infection defence (Rakoff-Nahoum, Medzhitov 2008). IECs mediate 
defence mechanisms by expressing PRRs, and by secreting cytokines and antimi-
crobial proteins, and by up-regulating surface molecules (Abraham, Medzhitov 
2011). Phagocytosis and autophagy mediate the killing of microbes. Intestinal LP 
macrophages are distinct from blood monocytes and retain active phagocytic and 
bactericidal activity (Smythies et al. 2005). In clearance of intracellular components, 
autophagy is a crucial mechanism. In autophagy, response to invasive bacteria, in-
tracellular sensors nucleotide-binding oligomerization domain (NOD) 1 and NOD2 
are essential because they recruit the autophagic protein ATG16L1 to the site. Mu-
tant NOD2 fails to recruit ATG16L1, resulting in impaired autophagy (Travassos et 
al. 2010). The IL-23/Th17 cell pathway defends against microbial infection, but the 
activated Th17 cell produces IL-23 and other cytokines that contribute to tissue in-
flammation (Hue et al. 2006). Mucosal responses actively regulate these cytokines. 
Secretion of intestinal IgA also reduces microbe penetration (Macpherson et al. 
2008).  
Association of IBD with variants in IL23R and genomic regions including other 
loci in the IL-23/Th17 pathway indicates that this pathway plays an important role in 
regulating intestinal immune homeostasis (Barrett et al. 2008).  
2.3 Intestinal manifestations of disease 
2.3.1 Crohn’s disease 
Inflammatory bowel disease (IBD) comprises different disease entities: Crohn’s 
disease, ulcerative colitis (UC), and unclassified colitis. Of these, Crohn’s disease 
was traditionally considered to be a predominantly Th1 type of disease and ulcera-
tive colitis a Th2 type. In Crohn’s disease versus UC, different T cell populations 
aberrantly are activated (Fuss et al. 1996). Discovery of Th17 cells made, however, 
this dichotomy invalid. Populations in northern Europe and North America have the 
highest prevalence of IBD indicating the role of the westernized lifestyle and envi-
ronment in IBD pathogenesis. Factors associated with IBD are smoking, diets high 
in fat and sugar, use of medication, stress, and high socioeconomic status (Ahuja, 
Tandon 2010, Danese et al. 2004).  
Crohn’s disease is an intestinal disease also called terminal ileitis, regional en-
teritis, granulomatous ileitis, hyperplastic ileitis, chronic ulcerative ileitis, and intes-
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tinal phlegmon. Crohn, Oppenheimer and Ginzburg in 1932 were the first to de-
scribe regional ileitis, later called Crohn’s disease (Crohn et al. 1984). Crohn’s dis-
ease is a chronic disease characterized by periods of inactive disease (remission) 
interrupted by acute flares of inflammation (relapses); sometimes the disease may be 
constantly active (chronically active disease). The site of inflammation may be any-
where from the mouth to the anus, and lesions in both sites are typical. The most 
prevalent site in the intestine is the terminal ileum, but inflammation may affect any 
part of the intestine. Typical lesions in the intestine are aphtous ulcerations. Lesions 
are patchy with intervening normal tissue. Under a microscope, the inflammation is 
transmural. Its hallmark is granulomatous inflammation.  
Crohn’s disease manifests in young people with its incidence highest between 
ages 15 to 30, and with 25 to 35% developing the disease before the age of 20 (Mes-
tecky et al. 2005). Early-onset IBD is likely to be more extensive and aggressive 
than is adult-onset IBD (Turunen et al. 2009). In pediatric patients, Crohn’s disease 
often manifests as colonic disease, with the upper GI tract also being commonly 
involved (Biank et al. 2007, Heyman et al. 2005).  
Pathogenesis 
A hypothesis is that a breakdown in tolerance is central to the immune pathogenesis 
of IBD (MacDonald 1995). Only limited evidence confirms this, however. The 
pathogenesis of Crohn’s disease is incompletely resolved, and currently the general 
hypothesis is still accepted: in genetically predisposed individuals, exposure to dis-
tinct environmental factors results in a dysregulation of the mucosal immune system. 
In Crohn’s disease, innate immunity abnormalities associate with the gene variants 
of NOD2, ATG16L1, and IRGM, which encode microbial recognition mediators. 
NOD2, also designated CARD15, was, in western populations, the first gene associ-
ated with Crohn’s disease susceptibility (Hugot et al. 2001, Ogura et al. 2001, Ham-
pe et al. 2007, Parkes et al. 2007). Three variants of NOD2 exhibit the strongest 
Crohn’s disease association, leading to an increased risk for developing Crohn’s 
disease that is 2- to 4-fold (Economou et al. 2004). Muramyl dipeptide (MDP) is a 
peptidoglycan in the cell wall of Gram+ and Gram- bacteria; NOD2 is a cytoplasmic 
receptor for MDP (Girardin et al. 2003).  
Traditional views are of Crohn’s disease as a Th1 type of disease, IL-12 being 
the key inducer of Th1 cells. Finding the key role of the IL-12 family in IBD patho-
genesis supports this classification (Neurath et al. 1995). The factor behind the re-
lapsing nature of the disease may be colitogenic Th17 cells (Kanai et al. 2009). 
The immunological background may vary between early-onset and adult-onset 
IBD (Henderson et al. 2011, Nieuwenhuis, Escher 2008). Epithelial chemokine pro-
duction is linked only with early-onset Crohn’s disease (Damen et al. 2006), and in 
both pediatric and adult IBD patients, intestinal immunoregulation fluctuates (Kuga-
thasan et al. 2007, Damen et al. 2006). 
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2.3.2 Ulcerative colitis 
Continuous inflammation limited to the large intestine characterizes ulcerative coli-
tis. Typically, the inflammation is most severe in the rectum (proctitis) and some-
times spreads to the whole large intestine. In the acute phase, lesions are continuous 
bleeding ulcerations and edema. Chronic disease results in fibrosis and polyps. Mi-
croscopy shows infiltration of glands by neutrophils, and their number gradually 
falls; the inflammation is present only in the LP.  
Clinically, the hallmark of UC is bloody diarrhea with or without mucus. The 
first description of UC appeared long before Crohn’s disease, in the mid-19th centu-
ry, by Samuel Wilks (Danese, Fiocchi 2011). Compared to Crohn’s disease, UC has 
a higher incidence and is more prevalent among adults. In Finland, UC continues to 
be more common in spite of the increase in prevalence of Crohn’s disease in be-
tween 1987 and 2003 (Lehtinen et al. 2011). 
Originally UC was thought to be a Th2-driven disease, but this dogma changed 
after observations that IL-13 and IFN-γ are both elevated in UC mucosa, and that 
colonic IL-4 is absent from UC. Thus, UC represents a quite superficial epithelial 
injury disorder (Siegmund, Zeitz 2011).  
Pathogenesis 
The working hypothesis for the pathogenesis of UC suggests that UC consists of a 
heterogeneous group of diseases with similar yet distinguishing phenotypes (Mes-
tecky et al. 2005). Genetic, subclinical, and clinical varieties exist and play a role in 
the intestinal inflammation seen in UC (Mestecky et al. 2005). The genetic back-
ground is less dominant in UC than in Crohn’s disease: a meta-analysis of genetic 
studies shows an association of 47 loci with UC, with only 19 of them specific to 
UC and 28 being also present in Crohn’s disease (Anderson et al. 2011). These asso-
ciations link to epithelial barrier dysfunction (ECM1, HNF4A, CH1, LAMB1), 
apoptosis and autophagy (DAP), and defects transcription regulation (IL23R, JAK2, 
STAT3, IL12B, PTPN2). In addition, UC shares risk loci associated with other im-
mune-system-mediated diseases (HLA and genes participating in Th1 and Th17 
differentiation, such as IL10, IL17R, IL23R, and IFN-γ).  
 
Autoantibodies are characteristic of various autoimmune diseases; in UC, an asso-
ciation exists with perinuclear antineutrophil cytoplasmic antibodies (pANCA) and 
IgG1 antibodies against colonic epithelial antigen exists (Bhagat, Das 1994, Seibold 
et al. 1998). About 70% of UC patients present with the circulating autoantibody 
pANCA, which reacts to the mucosal pANCA-reactive antigen and is related to a 
mucosal immune response (Saxon et al. 1990). The T-cell response to this antigen 
links T cell immunity to the autoantibodies (Mestecky et al. 2005)  
To maintain intestinal homeostasis requires a controlled innate immunity re-
sponse to the microbiota. Epithelial and immune cells house TLRs and NOD-like 
receptors, which recognize microbiota and affect the recognition process leading to 
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tolerance, or – if deregulated – leading to inflammation (Abreu 2010). Inflammatory 
bowel disease, regardless of the type of disease, shows increased production of pro-
inflammatory cytokines like IL1β, IL-6, TNF-α, and tumor necrosis factor-like ligan 
1 (Danese, Fiocchi 2011). To date, no definite evidence exists as to specific innate 
immune defects in UC. However, adaptive immunity abnormalities both in humoral 
and cellular aspects are associated with UC. In addition to elevated IgM, IgA and 
IgG levels, especially IgG1 antibodies increase in UC (Takahashi, Das 1985). Ac-
cording to the traditional Th division, UC is a Th2-type disease characterized by the 
colonic non-classical IL-13-secreting NK T cells. These cells lead to cytotoxity in 
epithelial cells, to apoptosis, and dysfunction of the epithelial barrier (Fuss et al. 
2004, Heller et al. 2005). Moreover, in UC, IL-5-secreting Th2 type T cells prevail, 
and Th17 cells also occur in the mucosa of IBD patients (Fujino et al. 2003).  
2.3.3 Celiac disease 
Celiac disease is an autoimmune disease characterized by enteropathy caused by 
gluten (composed of two main proteins: gliadins and glutenins) in the diet. The 
hallmark of celiac disease is an increased rate of destruction of small intestinal sur-
face epithelial cells by inflammation. In the early phase of celiac disease, only in-
flammatory cells are infiltrating the epithelium; compensation for loss of epithelial 
cells is by an increased rate of proliferation of cells in the crypts; these are conse-
quently elongated. When proliferation fails to compensate for the loss of epithelial 
cells, the villi are gradually lost, and even the remaining flat epithelium becomes 
made up of immature epithelial cells (Lindfors et al. 2010). Small-intestinal destruc-
tion in celiac disease manifests with malabsorption symptoms in young children 
under the age of two: abnormal stools, impaired growth, abdominal distension, mus-
cle wasting and hypotonia, and poor appetite. In older children and adults, these 
symptoms may be absent, and other intestinal complaints, such as abdominal pain, 
constipation, and bloating prevail. Iron deficiency anemia is the most common nutri-
tional deficiency (Savilahti et al. 2010). Currently the only treatment for celiac dis-
ease is a lifelong gluten-free diet (GFD) diet. The prevalence of celiac disease is 
rising and has doubled in Finland over the decades: 1.05% from 1978 to 1980 and 
1.99% from 2000 to 2001 (Lohi et al. 2007). This increasing prevalence is not due 
solely to efficient detection, but most likely depends partly on unknown environ-
mental factors. 
In addition to the environmental factors, a genetic predisposition is necessary. 
Celiac disease occurs mainly in genetically susceptible individuals and associates 
with HLA II genes; most patients are either HLA-DQ2+ or HLA-DQ8+. The absence 
of these HLA types has a negative predictive value for celiac disease that is close to 
100% (Wolters, Wijmenga 2008).  
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Pathogenesis 
In the pathogenesis of the disease, an immunologic response to gliadin peptide mod-
ified by transglutaminase-2 (TG-2) plays a major role. Enhanced permeability chal-
lenges the usual intestinal homeostasis; for instance, the TJ system is less efficient, 
partly due to upregulation of zonulin. In addition, the Th1 type of inflammatory 
cytokines, like TNF-α and IFN-γ, enhance intestinal permeability and potentiate the 
access of gliadin to the LP and the subsequent intestinal damage (Lionetti, Catassi 
2011). In the LP a cascade leading to celiac disease occurs: the adaptive immune 
response to gluten-derived peptides causes intestinal destruction. APCs housing 
HLA molecules (DQ2/DQ8) present gluten peptides and induce a CD4+ T-cell re-
sponse. Preceding deamination, tissue TG-2 converts glutamine into negatively 
charged glutamic acid, and deaminated gliadin peptide binds to HLA molecules with 
high affinity (Molberg et al. 1998). Activated CD4+ T cells promote inflammatory 
effects by secreting pro-inflammatory cytokines, followed by secretion of matrix 
metalloproteinases from fibroblasts or LP mononuclear cells (Lionetti, Catassi 
2011). Activated CD4+ T cells also secrete Th2-type cytokines, causing activation 
and clonal expansion of B cells that differentiate into plasma cells and produce anti-
gliadin and anti-tTG antibodies. This inflammation reduces the ability of epithelial 
cells to adhere to the basal membrane. At the same time, the apoptosis of epithelial 
cells is increased; these phenomena result in the increased destruction of villous 
epithelial cells.  
In potential celiac disease, the normal mucosal architecture prevails, but in the 
intestine, elevation of the density of γδTCR+ intraepithelial lymphocytes occurs and 
celiac disease-associated antibodies against tissue transglutaminase (TGA) appear in 
the peripheral blood (Holm et al. 1992, Arranz et al. 1994, Kaukinen et al. 1998). In 
addition, manifestation of serum endomysium autoantibodies predicts future celiac 
disease (Maki, Collin 1997, Kaukinen et al. 2007). 
2.3.4 Type 1 diabetes 
Unlike the diseases already discussed, T1D is not traditionally considered an intesti-
nal disease, but instead, is considered an endocrinal disease characterized by β-cell 
destruction in the pancreas resulting in failure of insulin secretion and thereby lead-
ing to high plasma-glucose levels. T1D predominantly affects young children, with 
half of the new cases younger than 15.  
Pathogenesis 
T1D is an immunological disease developing in genetically predisposed individuals: 
it associates with HLA DQB1*0302 and 02 alleles. First, during the pre-diabetic 
phase, circulating autoantibodies in blood are detectable. Later, T-cell-mediated 
immune mechanisms cause the death of insulin-producing beta cells in the pancreas 
to the extent that clinical diabetes ensues (Vaarala et al. 2008). In fetal development, 
the pancreas originates from the gut endoderm thus sharing the same biological 
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background as the intestine. In pancreatic islets, the endothelium expresses the mu-
cosal homing receptor MadCAM-1 (Hanninen et al. 2007).  
Animal models were the first to show the intestinal aspect of the disease: diet 
modulated the development of autoimmune diabetes (Elliott et al. 1988). Studies 
have shown that approximately half of all the children with T1D present with sub-
clinical intestinal immune activation in their intestinal specimens (Westerholm-
Ormio et al. 2003, Auricchio et al. 2004). Preceding the clinical onset of T1D, small-
intestinal enteropathy already exists (Bosi et al. 2006). High gut permeability also 
associates with early onset autoimmune diabetes in an animal model of Bio-
Breeding rats (Visser et al. 2010). Nevertheless, based on current evidence, not only 
does the leaking gut cause pancreatic beta-cell destruction, but intestinal inflamma-
tion also contributes to it. Evidence exists that enteric infection contributes to the 
destruction of the intestinal epithelial barrier leading to the activation of beta-cell-
specific autoimmunity in pancreatic lymph nodes, and thus affecting the develop-
ment of insulitis and beta-cell destruction (Graham et al. 2004, Watts et al. 2005, 
Watts et al. 2005, Neu et al. 2005). Enteric infections associate with epithelial cell 
destruction (Jalonen et al. 1991, Coyne, Bergelson 2006).  
Control of Th17 cells occurs in the gut, especially in the small intestine. Accord-
ing to a recent study, the Th17 cells navigate to the duodenum to be either eliminat-
ed or re-programmed to gain regulatory and immunosuppressive features (Esplugues 
et al. 2011). In peripheral blood samples, activated IL-17 immunity associates with 
human T1D (Honkanen et al. 2010); these IL-17+ T-cells also express CCR6, a 
chemokine receptor for Th17, indicating abilities for mucosal homing. In T1D, Th 
17 immunity presents with plastic Th17 cells capable of secreting various cytokines 
such as IL-9, IFN-γ, and IL-22. 
2.3.5 Immunomodulation by medication 
Immunomodulation by TNF-α-blocking agents 
TNF-α is a protein derived from mononuclear phagocytes; neutrophils, lymphocytes, 
NK cells, mast cells, and endothelium also produce it. When interacting with endo-
thelial cells, TNF induces intercellular adhesion molecule 1 (ICAM-1), vascular cell 
adhesion molecule 1, and E-selectin, thus causing migration of granulocytes to the 
infective site. TNF activates neutrophils and mediates adherence, chemotaxis, 
degranulation, and the respiratory burst. TNF share many biologic activities with IL-
1, but unlike IL-1, TNF has no direct effect on lymphocyte proliferation (Commins 
et al. 2010).  
TNF-α-blocking agents include infliximab, adalimumab, and certolizumab. In-
fliximab is an intravenously administered chimeric monoclonal IgG1 antibody 
which binds both circulating and membrane-bound human TNF-α. Infliximab induc-
es a cell-mediated cytotoxic reaction, enhances apoptosis of activated T cells, and 
causes elimination of TNF-α-expressing cells (Triantafillidis et al. 2011). Ada-
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limumab is a subcutaneously administered human IgG1 type anti- TNF-α monoclo-
nal antibody. Certolizumab pegol is a subcutaneously administered humanized TNF-
α-binding Fab´ fragment of an IgG antibody attached to an ethylene glycol moiety. 
The USA currently approves certolizumab, but in Europe only Switzerland does so 
(Triantafillidis et al. 2011).  
Opportunistic infections, malignancies, and infusion/injection reactions comprise 
the most important side-effects concerning TNF-α-blocking agents (Triantafillidis et 
al. 2011). Formation of antibodies to infliximab (human antichimeric antibodies, 
called HACA) leads to infusion reactions, loss of response, and serum-sickness-like 
delayed reactions. Screening for latent tuberculosis is necessary. Around 30% of 
patients with refractory Crohn’s disease are resistant to infliximab therapy. Patients 
with biologically active inflammation (increased CRP) are the best responders to 
infliximab. Smokers are less likely to respond (Rutgeerts et al. 2006). 
Immunomodulation related to IL-17 
Immunomodulation by IL-17 or IL-17R-blocking agents is the next step in the 
search for new medications against autoinflammatory diseases. Ixekizumab is a 
subcutaneously administered humanized monoclonal IgG4 anti-IL-17 antibody. It 
improves clinically evident symptoms of psoriasis, a chronic skin disorder (Leonardi 
et al. 2012). Brodalumab, on the other hand, is an intravenously administered human 
anti-IL-17RA monoclonal antibody that antagonizes the IL-17 pathway and im-
proves plaque psoriasis (Papp et al. 2012). 
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3 Aims of the study 
The purpose of this study was to evaluate the role of IL-17 immunity, the expression 
patterns of immunological markers associated with the IL-17 type of immunity, and 
the role of regulatory CD4+ cells in the intestine in disorders of the gut.  
The intestinal markers for regulatory T cells and effector T cells (Th1, Th17) were 
therefore characterized: 
  
• in adult patients with active and inactive Crohn’s disease treated with 
conventional treatment 
• in adult patients with Crohn’s disease treated with TNF-α-blocking 
agents 
• in children with inflammatory bowel disease 
• in children with celiac disease or type I diabetes 
 
 
 
  
? ? Mucosal IL-17 immunity  
???in disease 
 
 THL — Research 94/2012 40 
 
4 Patients and methods 
4.1 Adults with Crohn’s disease 
4.1.1 Patients receiving conventional therapy 
At the Helsinki University Central Hospital, one group comprised 24 adult Crohn´s 
disease patients with ileal or ileocolic disease referred to ileocolonoscopy (Table 1). 
The Vienna classification (Gasche et al. 2000) served to classify the Crohn’s disease 
diagnosis that was based on the clinical, endoscopic, radiologic, and histologic find-
ings. The Crohn’s disease diagnosis of four patients relied on their current endo-
scopic and histological findings. Pregnancy, history of an extensive bowel resection 
(ileosigmoideostomy, ileorectostomy), ostomy, longterm use of NSAIDs, or symp-
toms related to perianal fistulizing disease served as exclusion criteria. At the time 
of endoscopy (±2 weeks), patients completed a diary for the Crohn’s disease activity 
index (CDAI) (Best et al. 1976), and provided a stool sample and a heparinized 
blood sample. The Crohn´s disease index of severity (CDEIS) served to grade the 
endoscopy findings (Mary, Modigliani 1989). Endoscopic signs of active ulcerative 
inflammation in the ileum verified by active inflammation in ileal samples in routine 
histology served as criteria for active disease. As criteria showing inactive disease, 
all 13 patients in the remission group had macroscopically normal mucosa in routine 
histology. In endoscopy, 10 of them had an uninflamed ileum and 3 mild inflamma-
tory activity. Both patient groups showed either ileal or ileocolic disease. The con-
trol group comprised 14 patients referred to endoscopy for the following indications: 
change in bowel habits in 3, diverticular disease in 2, colorectal cancer follow-up in 
2, history of polyps in 1, history of adenoma in 2, rectal bleeding in 2; exclusion of 
Crohn’s disease for one was history of perianal abscesses and for one was ab-
dominal pain. All control subjects, in routine histological analysis of ileal biopsies, 
showed normal findings. Fecal samples were available from nine patients with ac-
tive and 11 patients with inactive disease. In addition, 10 healthy adults provided 
fecal samples.  
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Table 1. Characteristics of patients in Study I. Data as medians (with ranges).  
  References Inactive disease Active disease 
Gender  5M/9F 5M/8F 6M/5F 
Age in years 57.5 (22.0-74.1) 37.3 (22.7-53.2) 30.6 (20.0-51.3) 
Disease duration in 
years - 7.5 (3.3-31.1) 3.0 (0-26.7) 
CDAI  - 78 (2-136) 156 (0-605) 
CDEIS  - 1.3 (0-3.2) 9.5 (4.0-26.0) 
f-Calprotectin (µg/g)  -  62 (11-177) 969 (53-2284) 
Maintenance treatment    
     no medication 14 0 5 
     5ASA - 9 4 
     SASP - 1 2 
     thiopurine - 10 5 
     methotrexate - 0 1 
     metronidatzole - 0 1 
     corticosteroids - 1 2 
5-aminosalicylic acid (5ASA), sulfasalazine (SASP) 
4.1.2 Patients receiving anti-TNF-α-blocking agents 
At Helsinki University Central Hospital, 13 adult Crohn’s disease patients under-
went ileocolonoscopy twice: a baseline endoscopy and at 12 weeks a treatment-
response evaluation. CDEIS served to assess the endoscopy findings: scores < 3 
suggested inactive disease, and ≥ 3 endoscopically active disease (Mary, Modigliani 
1989, Sipponen et al. 2008). CDAI served to evaluate the clinical activity (Best et al. 
1976). At the time of endoscopies, patients also provided blood and fecal samples 
(Table 2). Following the baseline endoscopy, all patients received anti-TNF-α thera-
py (median 7 days afterwards, range 1-38 days): infliximab infusions 5 mg/kg took 
place at weeks 0 and 8. At week 0, one patient received a subcutaneous induction 
dose of 80 mg adalimumab, followed by 4 doses of 40 mg subcutaneously every 
other week; thereafter, at 10 weeks she underwent the control endoscopy. Prior to 
the introduction of anti-TNF-α-therapy, no changes in medication occurred, but 
afterwards their use of corticosteroids diminished.  
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Table 2. Characteristics of patients in Study II. Data as medians (with ranges). 
 Reference patients 
Crohn’s disease 
patients before 
treatment 
Crohn’s disease 
patients at 3-month 
follow-up 
Gender 5M/9F 6F/7M  
Age in years 58 (22-74) 23 (19-44)  
Disease duration in 
years - 5.1 (0.4-27.0)  
CDEIS - 14.4 (1.8-25.3)* 4.4 (0.0-11.2) 
CDAI - 174 (50-605)** 64 (24-112) 
f-Calprotectin (µg/g)  1173 (88-15326)*** 127 (13-1419) 
C-reactive protein 
(mg/l)  8 (<5-42)
§ <5 (<5-6) 
Inflammatory disease - 6  
Stricturing disease - 4  
Inflammatory and 
perianal disease - 3  
Ileal disease - 2  
Colonic disease - 3  
Ileocolonic disease - 8  
Medication - 13 13 
    azathioprine/6- 
      mercaptopurin - 9 11 
    methotrexate - 2 2 
    corticosteroids  - 9 0 
    mesalamine - 9 8 
    salazosulfapyridine - 2 2 
    metronidatzole - 1 0 
Previous anti-TNF-α-
treatment - 4  
*P=0.006, ** P=0.003, *** P=0.002, § P=0.012 
4.2 Pediatric patients 
4.2.1 Children with inflammatory bowel disease  
At the Children’s Hospital of University of Helsinki, we obtained ileal and colonic 
biopsy specimens from 29 pediatric patients undergoing diagnostic ileo-colonoscopy 
for exclusion of IBD: 8 Crohn’s disease, 11 UC, and 10 control patients. The Len-
nard-Jones criteria (Lennard-Jones 1989) served to establish the IBD diagnoses. The 
endoscopy allowed taking biopsy specimens from the distal ileum and colon for 
routine histology and study purposes: immunohistochemical and quantitative RT-
PCR studies. All children also underwent upper GI endoscopy, and all control sub-
jects showed normal findings in routine histological analyses of biopsies (Table 3).  
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Table 3. Characteristics of patients in Study III. Data as medians (with ranges). In addition to medi-
cation, one Crohn’s disease patient also took Saccharomyces Boulardii and one ulcerative colitis 
patient omepratzole. 
 
Reference  
children 
Crohn’s  
disease 
Ulcerative  
colitis 
Patients 14 12 13 
Intestinal biopsy  
   and blood samples 4F/6M 2F/6M 4F/6M 
Only blood sample 2F/2M 1F/3M 3M 
Age in years 7.7 (2.3-15.3) 13.6 (9.1-18.5) 12.3 (2.6-16.3) 
Disease duration in 
   years - 2.5 (0-15.6) 0 (0-6.1) 
C-reactive protein  
   (mg/l) <5 (<5-27) 15 (<5-45) 28 (<5-64) 
Erythrocyte  
   sedimentation rate 
   (mm/h) 
7 (2-30) 27 (7-102) 31 (2-53) 
Hemoglobin (g/l) 133 (125-150) 125 (109-142) 110 (103-150) 
Blood leucocyte 
   count (10E9/l) 6.3 (3.5-18.0) 5.6 (3.2-17.4) 9.3 (5.4-18.0) 
f-Calprotectin (µg/g) 31 (1-103) 1226 (268-2010) 952 (73-2604) 
No medication  14 8 7 
    Azathioprine - 2 1 
    Corticosteroids - 2 1 
    Mesalamine - 1 5 
    Metronidatzole - 1 2 
 
4.2.2 Children with celiac disease  
Study IV comprised 108 patients both from Sweden and from Finland (Table 4). The 
Finnish population comprised 71 patients undergoing capsule endoscopy at the 
Children’s Hospital of the University of Helsinki. None of them fulfilled diagnostic 
criteria of celiac disease as established by the European Society of Pediatric Gastro-
enterology, Hepatology and Nutrition (Troncone et al. 2004). Of the 32 patients 
classified with celiac disease, none had been on a gluten-free diet, and all showed 
adequate structural changes in the intestine. Five patients had suspected celiac dis-
ease (Ferguson et al. 1993). Reference children comprised 15 undergoing endoscopy 
for clinical reasons such as stomach ache. They showed no positive antibodies relat-
ed to celiac disease before the endoscopy, and a pathologist classified their biopsy 
specimens as healthy.  
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Table 4. Celiac disease patient characteristics in Study IV. Data as means. 
 Reference 
Potential 
celiac 
disease 
Celiac 
disease 
Celiac 
disease, 
gluten-free 
diet 
Patients 32 15 45 16 
Gender 11M/21F 6M/9F 15M/30F 5M/11F 
Age in years 8.7 11.7 9.0 6.4 
 
4.2.3 Children with type 1 diabetes 
Within Study IV, we had 19 children with T1D. Of these, 13 had previously estab-
lished T1D, and their biopsies served to exclude celiac disease. In addition to T1D, 6 
had also celiac disease (Table 5). 
 
Table 5. Type I diabetes patient characteristics in Study IV. Data as medians (with ranges). 
 T1D T1D+CD 
Patients 13 6 
Gender 11M/2F 3M/3F 
Age in years  9.3 (2.6-15) 9.7 (2.3-13.8) 
Disease duration in years 4.5 (0.3-11.7) 3.7 (1.3-9.5) 
 
4.3 Samples 
Ileocolonoscopy was performed with a colonoscope to obtain specimens from the 
colon and distal ileum in Studies I, II, and III. In Study IV, a tissue sample from the 
distal duodenum or the proximal jejunum was acquired by a Watson capsule biopsy 
device or a gastroscope. In Studies III and IV, all the children underwent endosco-
pies under general anesthesia. 
In the laboratory, the specimens were embedded in optimal cutting temperature 
(OCT) compound (Miles Laboratories), snap frozen, and stored at -80°C. For im-
mununohistochemical staining, frozen tissue samples were cut into 7-µm sections, 
and thereafter coded and evaluated by a person blinded to specimen identity. 
4.4  Immunohistochemistry  
4.4.1 Immunoenzymatic labeling 
Intestinal biopsy specimens from the ileum and the colon intended for immunohisto-
chemistry were embedded in optimal cutting temperature compound (Miles Labora-
tories), and thereafter frozen and stored at -80ºC until used. Prior to immunohisto-
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chemical staining, the tissue was cut into 7-µm sections. The avidin-biotin immun-
operoxidase system served as the stain for the frozen sections, in which the Vec-
tastain ABC Elite kit (Vector Laboratories, Burlingame, CA, USA) was used ac-
cording to the kit instructions. After acetone fixation, the slides were blocked in 
normal serum for 30 minutes. Mouse monoclonal antibodies and one rabbit polyclo-
nal antibody (Table 6) served as the primary antibodies, and the slides were incubat-
ed for one hour. Methanol-0.5% hydrogen peroxide for 20 minutes quenched the 
endogenous peroxidase activity. Thereafter, the slides were incubated in biotinylated 
antibody and in ABC reagent for 30 minutes each. The chromogen we used, 9-
amino-ethyl-cardatzole, and thereafter the slides were counterstained with Harris 
hematoxylin, and were washed in PBSbetween the staining-protocol steps. Omission 
of the primary antibodies created the negative controls. Prior to immunostaining of 
cytokines and FOXP3, the slides were incubated in 0.1% PBS-Tween20 for 10 
minutes at room temperature to make the tissue permeable. 1% normal serum in 
0.1% PBS-Tween20 was used to dilute the intracellular antibodies, and then the 
slides were incubated with the antibodies for one hour at +37oC in a humified cham-
ber.  
 
Table 6. Antihuman antibodies used for the immunihistochemical stainings. 
Antibody Dilution Company Clone Study 
CD4 1:20 BD Pharmingen RPA-T4 I, II, III, IV 
CD8 1:200 Dakocytomation PK25 I, II 
γδ-TCR 1:50 Endogen 5A6.E9 I,  
CD25 1:50 Neomarkers 143-13 I 
CD19 1:100 Dakocytomatin HD37 I 
IFN-γ 1:50 Mabtech 1-D1K I, III 
TNF-α 1:50 Biosource International 68B6A3L1 I 
CTLA-4 1:20 BD Pharmingen BNI3.1 I 
FOXP3 1:40 Abcam 236A/E7 I, II, III, IV 
IL-4 1:50 Mabtech IL4-II I 
IL-10 1:100 R&D Systems 23738 I 
IL-12p70 1:100 R&D Systems 24945 I 
IL-17 1:200 Santa Cruz Biotehcnology rabbit polyclonal I, II, III, IV 
IL-18 1:100 MBL/ R&D systems 125-2H I 
IL-23(p19) 1:10 GenWay DCS100.1 I 
 
4.4.2 Microscopic evaluation 
Data evaluation was done blinded to the clinical data. The number of positively 
stained cells in the LP was counted systematically under a light microscope through 
a calibrated eyepiece graticule 10x. In Study I, an Olympus BX50 light microscope 
was used at 60x magnification. The positively stained cells were counted either in 
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the epithelium or residing in the LP. Epithelial staining with HLA-DR was graded 
from 1 to 3 according to the area of staining: 1 representing only the tips of the villi, 
2 all of the villi, and 3 the crypts as well. In Studies II to IV a Leica DM4000B light 
microscope served for counting the cells. Positively stained cells in approximately 
30 fields were counted at 100x magnification. The cell densities are expressed as a 
mean number of positive cells per millimetre (cells/mm) or square millimetre 
(cells/mm2), with analysis based on this number.  
4.5 Quantitative reverse transcriptase polymerase chain reac-
tion 
Analyses of target gene expression in the intestinal biopsy samples and the peripher-
al-blood mononuclear cells were performed by quantitative reverse transcriptase 
polymerase chain reaction (qRT-PCR). In Studies I to III, biopsies were disrupted in 
lysis buffer containing 140 mM beta-mercaptoethanol by grinding them with a pes-
tle in an Eppendorf tube. In Study IV, biopsies from Finnish subjects were dissected 
from a matrix of OCT compound and homogenized by pestle (Starlab, Ahrensburg, 
Germany) in a 0.5-ml Eppendorf tube containing 250 µl of lysis buffer (Sigma, St. 
Louis, MO, USA). In Studies I, II and IV, the GenElute Mammalian total RNA min-
iprep kit (Sigma) served for extracting total RNA from biopsies. In Study III, total 
RNA was isolated with a Qiagen RNeasy mini kit with optional QIAshredder ho-
mogenization and DNAse digestion steps (Qiagen, Hilden, Germany). RNA yield 
and purity was measured with a spectrophotometer (ND-1000, NanoDrop Technolo-
gies Inc, Wilmington, DE, USA). Reverse transcription was performed with Taq-
Man Reverse Transcription reagents (Applied Biosystems, Foster City, CA) (Studies 
I-IV), with additional treatment of 200 ng of total RNA with DNAse I (0.01U/µl) 
(Roche Diagnostics, Mannheim, Germany) to eliminate genomic DNA in Studies I 
and IV.  
From the Swedish children in Study IV, the Qiagen RNeasy mini kit and DNAse 
treated with the RNnse-free DNase Set (Qiagen) served to isolate total RNA from 
cryopreserved and homogenized biopsies. A spectrophotometer (ND-1000, 
Nanodrop Technologies) served to measure the RNA concentration and purity. 
QRT-PCR was performed with predesigned FAM-labeled TaqMan Gene Expression 
Assay reagents (Applied Biosystems) for selected cytokines and transcription factors 
(Table 7). Ribosomal 18s RNA served as the endogenous control in all tests. 
The quantities of target gene expression were analyzed by a comparative thresh-
old cycle (Ct) method as recommended by the manufacturer (Applied Biosystems). 
An exogenous cDNA pool calibrator was collected from PHA-stimulated peripheral 
blood mononuclear cells (PBMC) and considered as an interassay standard, to which 
normalized samples were compared. Ct stands for the difference between the Ct of 
the marker gene and Ct of the 18S gene, whereas Ct is the difference between 
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the Ct of the sample and Ct of the calibrator. Calculation of 2– Ct then gives 
the relative amount of target gene in the sample compared with the calibrator, both 
normalized to an endogenous control (18S). For presentations, the relative amounts 
(2– Ct) of target genes were multiplied by a suitable factor and expressed as rela-
tive units. If the samples’ Ct value failed to reach the quantitative level, the artificial 
value given was half of the lowest acceptable value on a relative-unit scale. 
 
Table 7. Primers in Studies I-IV. 
Primer Applied Biosystems, Cat. no Study 
IL-4 4327038 I 
IL-6 Hs00174131_m1 III 
IL-8 Hs00174103_m1 I 
IL-17A Hs00174383_m1 I, II, III, IV 
IL-22 Hs00220924_m1 III 
IL-23A p19 Hs00413259_m1 I, II 
FOXP3 Hs00203958_m1 I, II, III, IV 
IFN-γ 4327052 Hs0014143_m1 
I 
IV 
RORc Hs01076112_m1 IV 
TGF-β1 Hs00171257_m1 I 
TNF-α Hs00174128_m1 I, II 
Ribosomal 18S RNA Hs99999901_s1 I-IV 
 
4.6 Caco-2 cell culture and stimulation protocols 
ATCC (Teddington, UK) provided the human colon adenocarcinoma cell line (Ca-
co-2). For 6 days in a 75 cm2 flask, cells were grown in Eagles’s minimal essential 
medium (Sigma) containing 10% heat-activated and sterile-filtered fetal bovine 
serum supplemented with penicillin (0.1 g/l) and streptomycin (0.15 g/l) at +37°C 
and 5% CO2. Thereafter, the cells were plated on sterile 48-well plates (Greiner Bio-
One GmbH, Frickenhausen, Germany) and grown for 4 days at a density of 1.5 x 105 
cells/well and a final volume of 0.5 ml/well. The cells were incubated for 5 hours in 
+37°C, 5% CO2 in the combinations listed in Table 8. Thereafter, the cells were 
collected for analyses of target gene expression in the Caco-2 cells with qRT-PCR, 
in which total RNA was isolated (Sigma), reverse transcription was done with added 
DNAse treatment, and qPCR analyses were performed as described above for biopsy 
samples. Apoptosis markers were bcl-2(Hs00608023_m1) and BAX 
(Hs00180269_m1).  
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Table 8. Combinations in Caco-2 cell stimulation. 
  Cat. no Study 
S. minnesota LPS  10 or 100 ng/mL  I 
rhIL-17 1 or 50 pg/mL 11340176 I, IV 
TNF-α   IV 
S.minnesota LPS +  
   rhIL-17   I 
rhIL-17 + TNF- α   IV 
 
4.7 IL-17 levels in plasma and feces  
ELISA (Biosource, Camarillo, CA, USA) served for study of the concentration of 
IL-17 in plasma and feces. Fecal samples were homogenized with phosphate-
buffered saline (wt/vol ratio 1:1) on a shaker for 30 minutes at 4°C. These homoge-
nates were centrifuged for 15 minutes at 10,000 g at 4°C. The supernatants were 
collected and stored at -­‐70°C for subsequent analysis. 
4.8 Fecal calprotectin assays 
A quantative enzyme immunoassay (PhiCal Test, Calpro AS, Oslo, Norway) served 
for measurement of fecal calprotectin, and the values quoted as normal were <100 
µg/g of stool (Kolho et al. 2006, von Roon et al. 2007). 
4.9 Flow cytometry methodology 
Ficoll-Hypaque (Pharmacia, Uppsala, Sweden) density centrifugation served to sep-
arate the PBMCs from heparinized blood as previously described (Klemetti et al. 
1998). In CD4+CD25highFOXP3+ Treg cell analysis, staining of the cells was accord-
ing to the manufacturer's protocol (eBioscience, San Diego, CA, USA). First, mono-
clonal antibodies PerCP–anti-human-CD4 (Pharmingen) and PE–anti-human-CD25 
(Miltenyi Biotec) served for the cell surface staining. Then cells (1 x 106 cells / tube) 
were washed twice with 1 mL permeabilization buffer. After the surface staining, 
the sample was mixed with 1 mL fixation/permeabilization buffer, incubated at 
room temperature for 30 min, and washed twice with 2 mL permeabilization buffer. 
After that, cells were incubated for 15 min in RT with 1% normal mouse IgG in 100 
µl permeabilization buffer. For intracellular staining, 20 µL Alexa 488-conjugated 
FOXP3 antibody or rat immunoglobulin G2a isotype control was added to the reac-
tion system and incubated in a 4°C freezer for 30 min and rewashed twice with 2 mL 
permeabilization buffer. Then the stained cells were resuspended in a 1mL flow 
cytometry staining buffer and analyzed by flow cytometry with FACSDiva software 
(BD, Piscataway, NJ, USA).  
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4.10 Cytokine secretion from in vitro cultured biopsies 
Small-intestinal biopsy specimens were cultured for 72 hours in RPMI-5% human 
AB serum, and thereafter, a flow-cytometric bead array (Bender Medsystems) 
served to measure the concentration of IL-17, IL-1beta, and IL-6 secreted in the 
culture supernatants. To enable statistical analyses, samples below either the detec-
tion limit or below the cutoff level of the method were given half the cut-off value. 
4.11 Statistical analysis 
SPSS v 14.0 (I and II), SPAW Statistics 17.0 (III and IV) for Windows (SPSS Inc., 
Chicago, IL, USA) and GraphPad Prism software (San Diego, CA) served for the 
data analysis. The non-parametric Kruskall-Wallis test, Mann-Whitney U-test, Wil-
coxon signed rank test, Spearman’s rank correlation test, and Fisher’s exact test 
served for performance of statistical analyses. P-values < 0.05 were considered sig-
nificant. 
4.12 Ethical Considerations 
In Studies I and II, specimens from adult patients were taken for diagnostic purposes 
at the Helsinki University Central Hospital, Clinic for Gastroenterology. In Studies 
III and IV, Finnish pediatric patients underwent endoscopy for diagnostic purposes 
at the Children’s Hospital, Helsinki University Hospital. Written informed consent 
was obtained from all the adults participating in Studies I or II and from the parents 
or care-givers of the children participating in Study III. In Study IV, oral witnessed 
informed consent was available from the parents and from age-appropriate patients 
among Finnish patients. For the Swedish patients, written informed consent came 
from parents and children. 
The study plan for Studies I and II was approved by the Ethics Committee, De-
partment of Medicine, Helsinki University Central Hospital, Helsinki. The Ethics 
Committee of the Children’s Hospital, Helsinki University Central Hospital, Fin-
land, approved the study plan for Study III and for the Finnish patients in Study IV. 
For the Swedish patients, the Regional Ethics Committee for Human Research at the 
University Hospital of Linköping, Sweden approved the study plans. 
  
? ? Mucosal IL-17 immunity  
???in disease 
 
 THL — Research 94/2012 50 
 
5 Results and discussion 
 
 
 
Figure 3. Changes in immunological markers in the intestine. 
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Table 9. Immunological changes studied in Crohn’s disease. 
 
Th1/Th2 type im-
munity IL-17 type immunity Regulatory T cells 
Inactive Crohn’s  
   disease (I) 
IFN-γ+ cells ↔  IFN-
γ mRNA ↔ IL-4+ 
cells ↑  
(all in ileum) 
IL-17+ cells ↑  
IL-17 mRNA ↑  
IL-23p19+ cells ↑ 
IL-23 mRNA ↔  
IL-6mRNA ↑  
(all in ileum) 
FOXP3+ cells ↔ 
FOXP3 mRNA ↑  
(all in ileum) 
Active Crohn’s  
   disease (I) 
IFN-γ+ cells ↔  IFN-
γ mRNA ↔ IL-4+ 
cells ↑  
(all in ileum) 
IL-17+ cells ↑ 
IL-17mRNA ↑ 
IL-23p19+ cells ↑  
IL-23 mRNA ↑  
IL-6 mRNA ↑  
(all in ileum) 
FOXP3+ cells ↔ 
FOXP3 mRNA ↑  
(all in ileum) 
Crohn’s disease  
   before TNF-α- 
   blocking therapy  
   (II) 
IFN-γ mRNA ↑ (i&c)  
IL-17+ cells ↑(i)  
IL-17 mRNA ↑(c)  
IL-23 mRNA ↑ (i) 
FOXP3+ cells ↑ (i) 
FOXP3 mRNA ↑ (i&c) 
Crohn’s disease  
   after TNF-α- 
   blocking therapy  
   (II) 
IFN-γ mRNA ↑ (i&c)  
IL-17+ cells ↑ (i)  
IL-17 mRNA ↔ (i&c)  
IL-23 mRNA ↑ (i) 
FOXP3+ cells ↑ 
FOXP3 mRNA ↑  
(all in ileum)  
i = ileum, c = colon 
5.1 Th1 and Th2 type of immunity in Crohn’s disease 
Several studies show high colonic IFN-γ	  expression in Crohn’s disease and empha-
size the traditional dichotomy of Crohn’s disease as a Th1-type disease. In Study II, 
we saw increased intestinal IFN-γ before and after TNF-α-blocking therapy. Study I, 
however, showed no characteristics related to the Th1 immune response, such as 
IFN-γ	  or IL-12p70 expression (Figure 3, Table 9). Of course, one explanation as to 
why we see less constantly increased Th1 type of immunity could be the relative 
small number of patients. Altogether, our results suggest that in Crohn’s disease, 
Th17 immunity may play a more important role than does Th1 type immunity. Th1 
and Th17 types of immunity have been interconnected: Annunziato et al. (2007) 
suggest that some intestinal Th17 cell lines derived from Crohn’s disease patients 
are able to secrete IFN-γ. Transcription factor T-bet reciprocally regulates IL-17 and 
IFN-γ, supporting IFN-γ up-regulation but inhibiting the IL-17 axis by down-
regulating IL-23R transcription (Gocke et al. 2007). 
Most of the other studies showing, for example, a Th1 response in Crohn’s dis-
ease were focused on colon samples. In Crohn’s disease, tissue damage occurs most 
commonly in the ileum (Nikolaus, Schreiber 2007) emphasizing the need to study 
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the ileal changes as we did in Study I. It is possible that the balance between Th1 
and Th17 differs between ileum and colon, Th17 being more prominent in the ileum.  
Considering the earlier reports of IFN-γ	  expression in Crohn’s disease, our find-
ing of increased intestinal IL-4 response in Study I was somewhat unexpected 
(Table 9). The numbers of IL-4+ cells in the LP differed between study groups, be-
ing higher in Crohn’s disease than in the reference patients. The number of IL-4+ 
cells was higher in active than in inactive Crohn’s disease (Figure 4). Parronchi et al. 
(1997) reported a high number of activated CD4+	  T cells with no IL-4 reactivity in 
Crohn’s disease. IL-17 activation seems to be unable to down-regulate Th2-type 
stimulation in the form of elevated IL-4 levels, although some studies suggest that 
both IL-4 and IFN-γ inhibit the development of IL-17-secreting Th cells (Steinman 
2007). 
A unique subset of intestinal macrophages exists that produces proinflammatory 
cytokines such as IL-23, TNF-α, and IL-6 (Kamada et al. 2008). In Crohn’s disease, 
the number of these macrophages is high, and rather than IL-17 production, they 
contribute to IFN-γ production by LP mononuclear cells. IFN-γ triggers further ab-
normal macrophage differentiation, with hyperproduction of IL-23. Likewise, in 
Study II we showed enhanced ileal IFN-γ mRNA expression in Crohn’s disease. 
Double positive Th1+Th17+ mucosal cells and T cell lines are able to secrete both 
IL-17 and IFΝ−γ in Crohn’s disease to cause the related intestinal inflammation 
(Rovedatti et al. 2009, Annunziato et al. 2007). In Study II, the positive correlation 
between IL-17 and IFN-γ mRNA expression in ileal Crohn’s disease may reflect 
activation of these kinds of cells. Accordingly, in Study II, ileal and colonic IFN-γ 
and IL-17 mRNA expression correlated positively (r=0.636; P=0.026; r=0.539; 
P=0.021). Possibly, Th1+Th17+ cells produced IL-17 and IFN-γ, but because we 
lacked material to further characterize IL-17- or IFN-γ-producing cells, this question 
remains open. Unfortunately, methodological problems prevented us from accom-
plishing double staining of IL-17 or FOXP3 and surface markers. 
 
? ? Mucosal IL-17 immunity  
???in disease 
 
Results and discussion 
 
THL — Research 94/2012 53 
 
Activ e disease Remission References
0
500
1000
Kruskall-Wallis 0,0005
0,31
0,0002
0,012
IL
-1
7/
m
m
2
Activ e disease Remission References
0
100
200
500
1500
Kruskall-Wallis 0,025
0,684 0,052
0,012
IL
-2
3/
m
m
2
Active disease Remission References
0
100
200
300
400
Kruskall-Wallis 0,868
Fo
xP
3/
m
m
2
Activ e disease Remission References
0
50
100
150
200
Kruskall-Wallis 0,722
IF
N
-γ
/m
m
2
Activ e disease Remission References
0
50
100
150
200
200
400
600
Kruskall-Wallis 0,442
IL
-1
0/
m
m
2
Activ e disease Remission References
0
100
200
300
300
800
Kruskall-Wallis 0,0007
0,049 0,034
0,0004
IL
-4
/m
m
2
Activ e disease Remission References
0
500
1000
1500
2000
2500
3000
3500
4000
4500
Kruskall-Wallis 0,012
0,012
0,018
C
D
4/
m
m
2
Activ e disease Remission References
0
500
1000
1500
Kruskall-Wallis 0,013
0,03
0,005
C
D
8/
m
m
2
 
Figure 4. Immunohistochemical stainings in active and inactive Crohn’s disease (Study I). 
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5.2 Intestinal IL-17 activation in Crohn’s disease  
Evidence accumulates regarding the importance of the IL-23/IL-17 axis in animal 
models of IBD (Maloy 2008). Our results from humans support this view and indi-
cate IL-17 as a hallmark of Crohn’s disease, both in active and inactive disease. In 
Studies I and II, Crohn’s disease patients had increased amounts of intestinal IL-17- 
and IL-23-expressing cells, not only in active disease but also in clinical remission, 
providing a potential link to the cause of the disease and the basis for its relapsing 
nature.  
Earlier studies of Crohn’s disease report IL-17+ cells and high levels of IL-17-
specific mRNA in the colonic mucosa, but in normal intestinal mucosa, the number 
of IL-17-expressing cells is low (Fujino et al. 2003, Nielsen et al. 2003). Studies I 
and II support this finding: in Study I, the number of LP IL-17+ cells was elevated in 
Crohn’s disease, but showed no difference between the active and inactive disease 
(original publication I, Table 3). Likewise, the expression of IL-17A mRNA was 
elevated in Crohn’s disease when compared to that of the reference group, but no 
difference existed between active and inactive Crohn’s disease (original publication 
I, Figure 1). In Study II, the numbers of ileal and colonic IL-17+ cells were higher in 
Crohn’s disease both before and after TNF-α-blocking than in the reference patients 
(original publication II, Figure 2). At baseline, colonic IL-17 mRNA expression was 
higher in Crohn’s disease than in the reference group (Table 9).  
Fujino et al. (2003) reported colonic IL-17 expression to be higher in Crohn’s 
disease than in UC, and found that in active IBD the number of IL-17+ cells to be 
higher than in inactive IBD. Another study supports this view: inflamed colonic 
lesions showed elevated IL-17F mRNA expression compared to the uninflamed 
mucosa in Crohn’s disease, whereas intestinal IL-17F mRNA expression was higher 
in UC than in Crohn’s disease (Seiderer et al. 2008). Study I, however, showed no 
difference between patients with active or inactive Crohn’s disease as to the number 
of ileal cells or as to the level of IL-17-specific mRNA. The increased numbers of 
IL-17+ cells in both samples in Study II supports this. The difference in disease lo-
calization or the classification of activity of the disease may explain the discrepancy 
between Study I and the Fujino et al. results. Because we aimed to compare the ac-
tive phase of the disease (defined as endoscopically confirmed signs of active ul-
cerative inflammation) with the remission phase (defined as endoscopically con-
firmed uninflamed mucosa), we classified patients according to the endoscopic find-
ing, and with the CDEIS assessed the state of the disease.  
Unfortunately, we were unable to demonstrate IL-17-specific mRNA in PBMCs 
or increased circulating IL-17 levels in patients’ plasma, as reported earlier (Fujino 
et al. 2003). In Study I, plasma concentration of IL-17 was generally low, in most 
cases undetectable (in 12 of 14 control subjects and in 22 of 24 patients). Our find-
ings support the view that IL-17+ cells home to the gut immune system and do not 
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circulate in the periphery. When a specific treatment removes the detrimental effect 
of TNF-α, the role of IL-17 in the intestinal inflammation becomes evident. Three 
months after TNF-α-blocking, CDEIS correlated positively with magnitude of intes-
tinal IL-17 immunity in the amount of ileal IL-17+ cells (r=0.806, P=0.007) and IL-
17 mRNA (r=0.736, P=0.038), whereas this kind of correlation was absent before 
TNF-α-blocking. Following the treatment, lower IL-17 activity associated with en-
doscopic remission. The only patient with increasing CDEIS during treatment pre-
sented also with an increase in number of IL-17+ cells. Thus, TNF-α-blocking was 
unable to directly down-regulate the IL-23/IL-17 axis. However, changes in the 
immunological network, seen as a better balance between effector and regulatory T 
cells, mediated the beneficial effects of TNF-α-blocking (discussed in section 5.3).  
In active Crohn’s disease, CD4+ and CD8+ cells decreased, an unexpected find-
ing in Study I (Figure 4) and in Study II were absent. In remission, the number of 
CD4+ and CD8+ cells normalized, suggesting a regulatory function for either of the-
se cell types. The earlier study found the IL-17+ cells to be CD3+CD68+ in Crohn’s 
disease, suggesting that in inflamed mucosa both monocytes/macrophages and T 
cells produce IL-17 (Fujino et al. 2003). In Study I, the ratio of the IL-17+ cells to 
CD4+ or CD8+ cells was higher in Crohn’s disease than in the reference group, and 
the highest ratio of IL-17+ cells to CD4+ cells was in active disease (original publica-
tion I, Figure 2). Study II supports this phenomenon, as the ratio of ileal IL-17+ cells 
to CD4+ cells was elevated both before and after the anti-TNF-α treatment when 
compared to levels in the reference group (original publication II, Figure 3). Anti-
TNF-α treatment, however, reduced markedly the ratio of IL-17+ cells to CD4+ cells 
(original publication II, Figure 3). The ratio of ileal IL-17+ cells to CD8+ cells was 
higher before and after TNF-α blocking in Crohn’s disease than in the reference 
group (P=0.0001 and P=0.0031). Therefore, the normalization of the total number of 
CD4+ and CD8+ cells in inactive Crohn’s disease seen in Study I suggests the regu-
latory function of either of these cell types, something needing further characteriza-
tion. Despite the clinical and macroscopic improvement in symptoms after TNF-α-
blocking, the high numbers of activated T cells in the intestine may signify a need 
for continuous TNF-α-blocking. 
Innate immune cells such as dendritic cells produce IL-23, a cytokine that acti-
vates Th17 cells and seems to be an important factor in maintaining the production 
of IL-17 (Neurath 2007). IL-23 can induce intestinal inflammation without Th1, thus 
suggesting that IL-23 influences various aspects of tissue inflammation and damage 
(Hue et al. 2006, Kullberg et al. 2006, Uhlig et al. 2006, Marx 2007). This finding 
motivated us also to study IL-23 in Crohn’s disease. In Study I, the expression of IL-
23 mRNA was higher in active disease than in the controls (P=0.014). Study II con-
firmed this finding, in which the ileal IL-23 mRNA expression remained elevated 
both before and after TNF-α-blocking when compared to the levels in the reference 
group (Table 9). Our results show that even in the endoscopically confirmed healed 
mucosa, IL-17+ and IL-23+ cells still persisted (Figure 4). The high numbers of IL-
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17+ and IL-23+ cells in inactive disease explain the potential for the flaming of the 
disease and demonstrate that this immunological phenotype of the mucosa is funda-
mentally linked to Crohn’s disease. It also is likely linked to the pathogenesis of the 
disease, for example, by acting as a microbial stimulus, because IL-17 enhanced the 
inflammatory response of epithelial cells to LPS in vitro. 
In addition to their role as the first line of defence against bacterial invasion, in-
traepithelial lymphocytes participate in inflammatory and immune reactions. Intesti-
nal epithelial cells and isolated human intraepithelial lymphocytes constitutively 
express IL-8 mRNA and secrete low levels of IL-8 protein; even in response to LPS, 
Caco-2 cells expressed low amounts of IL-8 (Eckmann et al. 1993), which Study I 
also demonstrated. Pro-inflammatory cytokines and LPS have a synergistic effect: 
the effect of combinations of different cytokines (IL-1β, IL-2, IL-6, IFN-γ, TGF-β) 
and LPS on IL-8 secretion and the response to an individual cytokine in colonic 
epithelial cell lines were similar (Eckmann et al. 1993). Invasive bacterial infection 
induces expression and up-regulation of pro-inflammatory cytokines in IECs; for 
example, IL-8 and TNF-α (Jung et al. 1995). In this respect, our finding of enhanced 
IL-8 and TNF-α	  expression in LPS plus IL-17 stimulation in the intraepithelial cell 
line is interesting. We used Caco-2 cells, in the presence of IL-17 alone or in combi-
nation with LPS, to study the effect of IL-17 on ECs. Incubation of the Caco-2 cell 
line with S. minnesota LPS together with rhIL-17 induced higher expression of 
TNF-α	  and IL-8 mRNA than did LPS or rhIL-17 alone (original publication I, Fig-
ure 3). This could provide a link between enhanced IL-17 production, bacterial 
stimulus, and mucosal damage.  
Whereas IL-23 serves to maintain IL-17 production, IL-6 and TGF-β induce the 
development of human Th17 cells (Bettelli et al. 2007). This so intrigued us that we 
evaluated the level of IL-6- and TGF-β-specific transcripts in Study I. Expression of 
IL-6 mRNA was higher both in active and inactive Crohn’s disease (original publi-
cation I, Figure 1) than in the reference group. In addition, TGF-β-specific mRNA 
was higher in Crohn’s disease than in the reference group (P=0.031, with active and 
inactive groups pooled). In the presence of IL-6, TGF-β	  supports the induction of the 
Th17 phenotype, whereas these cytokines together suppress generation of induced 
FOXP3+ Tregs, as suggested by in vitro studies (Bettelli et al. 2006).  
After our finding of elevated IL-17 at both protein and transcriptional levels, we 
were keen to learn whether the mucosal damage in Crohn’s disease leads to high 
intestinal production of IL-17. We addressed this question by studying the fecal 
levels of IL-17 in Crohn’s disease (Study I). IL-17 fecal levels were elevated in 
active disease (P=0.05), but in general were low but detectable in about half of the 
patients with active Crohn’s disease (5 of 9), in only 1 of 11 patients with inactive 
disease, and in none of the healthy adults. 
In the active phase of Crohn’s disease, increased levels of fecal IL-17 demon-
strate elevated Th17 activity, which supports the role of IL-17 in tissue damage. In 
addition, an increased level of IL-23 transcription further supports the idea that in 
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active Crohn’s disease, IL-23 independently or via IL-17 causes mucosal damage. 
The findings of IL-23 as being a T-cell-independent inducer of mucosal inflamma-
tion (Hue et al. 2006), and of IL-23R polymorphism as being closely associated with 
Crohn’s disease (Duerr et al. 2006), suggests the latter interpretation. 
5.3 Regulatory T cells in Crohn’s disease 
Transcription factor FOXP3 characterizes Tregs, a non-comparable subset of T cells 
regulating immune response; a lack of FOXP3 leads to serious autoimmunity asso-
ciated with poor Treg development (Fontenot et al. 2003, Hori et al. 2003, Kim, 
Rudensky 2006, Rudensky 2011, Yamaguchi et al. 2011). A few studies address 
Tregs and their role in intestinal inflammation, and most of these studies reveal a 
concordant expansion of intestinal Tregs and suppression of Treg activity in vitro 
(Maul et al. 2005, Saruta et al. 2007, Yu et al. 2007). One study in IBD patients 
showed elevation of FOXP3+ cells in inflamed colonic mucosa, but a reduction 
when compared with other intestinal inflammatory diseases such as diverticulitis or 
infectious enteritis (Maul et al. 2005). We were, therefore, inspired to study the 
number of FOXP3+ cells and levels of FOXP3 mRNA in Crohn’s disease patients as 
well as in ileal samples.  
Our results showed up-regulation of FOXP3 in Crohn’s disease in all the sub-
groups: active disease, inactive disease, and treatment response after TNF-α-
blocking agent (Table 9). In Study I, FOXP3 mRNA expression was elevated both 
in active (P=0.0005) and inactive Crohn’s disease (P=0.009) compared to the ex-
pression in reference patients. This phenomenon occurred also in Study II, as the 
patients’ ileal samples both before and after TNF-α-blocking treatment showed an 
elevation in FOXP3 mRNA expression (P=0.023) and in numbers of FOXP3+ cells 
(P=0.005, original publication II, Figure 2). In addition, the number of colonic 
FOXP3+ cells was higher in Crohn’s disease in the 3-month samples than in the 
reference patients (Figure 5). The ratio of ileal FOXP3+ cells to CD4+ cells was 
higher in both, before (P=0.03) and after TNF-α-blocking treatment (P=0.03) than in 
the reference group. To conclude: in Study I, no up-regulation of FOXP3 was appar-
ent at cellular level, but in Study II, the up-regulation existed both at cellular and 
mRNA levels.  
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Figure 5. Immunohistochemical findings of IL-17- and FOXP3-positive cells in the intestine in 
Crohn’s disease (Study II). 
Reports find most FOXP3 cells to be CD4+CD25high cells, Tregs. FOXP3 expres-
sion, however, is not restricted to Tregs, because activation in CD4+CD25-cells in-
duces FOXP3 (Walker et al. 2003, Wang et al. 2007) leading to the impression that 
intestinal FOXP3-expressing cells may originate either in classical Tregs or in acti-
vated T cells. Induction of FOXP3 on activation, however, leads to development of a 
hyporesponsive T-cell phenotype with an impaired suppressive function. Transient 
FOXP3 expression may thus also exist in a nonsuppressive T-cell population (Wang 
et al. 2007). Our finding of up-regulated FOXP3 expression in active Crohn’s dis-
ease may be a signal from FOXP3 expression induced by T-cell activation and there-
fore mean imperfect suppressive capability. In remission, a high number of FOXP3+ 
cells may, however, reflect the number of natural, suppressive Tregs. 
In the presence of IL-6, TGF-β	   supports the induction of the Th17 phenotype, 
whereas these cytokines together sudppress the generation of induced FOXP3+ 
Tregs, as suggested by in vitro studies (Bettelli et al. 2006). Xu et al. (2007) suggest 
that, in the absence of exogenous TGF-β, FOXP3 Tregs can induce Th17 and may 
differentiate into Th17 cells. This shines new light on our findings of up-regulated 
FOXP3 together with IL-17 in Crohn’s disease. Interestingly, Study I showed close 
correlation between expression of FOXP3 and IL-17 at mRNA level in the active 
disease (r=0.817, P=0.007), whereas the reference group showed no correlation 
between these parameters (r=0.06, P=0.86).  
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In IBD, the balance between Th17 and Tregs cells has an important effect (Kanai 
et al. 2009). One study suggests that in IBD the relative number of FOXP3+ cells to 
effector cells is low and that no functional defect of Tregs appears (Makita et al. 
2004). In Study II, the ratio of ileal or colonic IL-17 or IFN-γ mRNA expression to 
FOXP3 mRNA expression showed no difference before or after the treatment. How-
ever, for protein expression a difference did exist: the ratio of ileal IL-17-expressing 
cells to FOXP3-expressing cells was higher at baseline than in 3-month samples 
(P=0.038, Mann-Whitney U-test, original publication II, Figure 4). Study II thus 
suggests a relative decrease in IL-17 immunity in relation to total number of 
FOXP3+ cells. The plasticity of Tregs may be one mechanism behind the beneficial 
change in balance between IL-17+ and FOXP3+ during TNF-α-blocking treatment. 
IL-17+ cells may arise from Tregs: in the presence of IL-6, CD4+CD25+FOXP3+ 
cells can differentiate to Th17 (Xu et al. 2007). TNF-α-blocking might inhibit this 
differentiation, because it blocks IL-6 production. This phenomenon may be reflect-
ed in the beneficial change in the balance between IL-17+ and FOXP3+ cells after 
TNF-α-blocking treatment. 
More recently, Baba et al. (2010) showed that TNF-α suppresses the develop-
ment of Th17 cells from naïve CD4 cells by means of mechanisms that, however, 
remain to fully explored. In Study II, TNF-α blocking did not manage to fully down-
regulate IL-17 immunity. The function of Tregs complicates this interaction, and an 
understanding of the complete relation between Th17 and Tregs is lacking. TNF-α-
blocking led to an improved balance between Tregs and IL-17 effector T-cells.  
A marked decrease in CDEIS was associated with a decreasing ratio of intestinal 
IL-17+ cells to the numbers of CD4+ cells and FOXP3+ cells. After TNF-α-blocking 
treatment, FOXP3+ or CD4+ cells and CDEIS showed no correlation, but at baseline, 
ileal FOXP3 mRNA expression and CDEIS correlated positively (r=0.830; P=0.041). 
The relative enhancement of regulatory mechanisms likely explains this clinical and 
endoscopic response to treatment. 
Considering changes in maintenance therapy is important when evaluating the ef-
fect of anti-TNF-α agents on immunological markers. Such changes may have an 
independent effect on these immunological markers, thus making interpretation of 
the results more challenging. Most patients in Study II received corticosteroid treat-
ment at the first administration of TNF-α blocking, but at the time of the second 
colonoscopy, none. Corticosteroids have multiple mechanisms to inhibit T cell acti-
vation (Leung, Bloom 2003), possibly through induction of Tregs. FOXP3 mRNA 
expression rises in asthma patients treated with glucocorticoids, both in adults and in 
pediatric patients (Karagiannidis et al. 2004, Hartl et al. 2007). In Study II, cortico-
steroid treatment was tapered off in most patients, excluding the possibility that 
corticosteroid use would explain the increase in relative number of FOXP3+ cells. 
(In active disease, but also after treatment, Study II showed increased numbers of 
FOXP3+ cells.) 
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In the inflamed mucosa, IL-17 and FOXP3 were activated similarly, regardless 
of the activation state of the Crohn’s disease. In Study II, TNF-α blocking induced 
mucosal healing that associated with beneficial changes in the balance between ef-
fector T cells and Tregs. Th17 cells surviving after treatment underline the need for 
maintenance therapy in order to avoid relapse.  
5.4 Immunological changes in pediatric IBD 
Table 10. Immunological changes studied in pediatric inflammatory bowel disease. 
 
Th1/Th2 type im-
munity IL-17 type immunity Regulatory T cells 
Crohn’s  
   disease IFN-γ mRNA ↑ 
IL-17+ cells ↑ (c) 
IL-17 mRNA ↑ (c)  
IL-17+ cells ↔ (i) 
IL-17 mRNA ↔ (i) 
IL-6 mRNA ↑ (c) 
IL-22 mRNA ↑ (c) 
FOXP3+ cells ↑ (c) 
FOXP3 mRNA ↑ (c) 
FOXP3+ cells ↔ (i) 
FOXP3 mRNA ↔ (i) 
Ulcerative  
   colitis IFN-γ mRNA ↑ 
IL-17+ cells ↑ (c) 
IL-17 mRNA ↑ (c) 
IL-17+ cells ↔ (i) 
IL-17 mRNA ↔ (i) 
IL-6 mRNA ↑ (c) 
IL-22 mRNA ↑ (c) 
FOXP3+ cells ↑ (c) 
FOXP3 mRNA ↑ (c) 
FOXP3+ cells ↔ (i) 
FOXP3 mRNA ↔ (i) 
 
Classification of colonic inflammation into Crohn’s disease and UC can be diffi-
cult (Heyman et al. 2005). Intestinal IL-17A and IL-17F mRNA expression is in-
creased in pediatric patients (Seiderer et al. 2008, Verdier et al. 2011). Interestingly, 
IL-17 elevation occurred in colonic mucosa also in UC, suggesting that pediatric 
IBD colitis is a Th17-related phenomenon irrespective of its clinical classification 
(Table 10). Crohn’s disease patients with endoscopically active disease as well as 
children with a macroscopically healthy ileum exhibit mucosal IL-17 activation. In 
pediatric IBD patients, IL-17 mRNA up-regulation occurred in colonic mucosa both 
in Crohn’s disease and in UC when compared to control levels (original publication 
III, Figure 1). The numbers of colonic of IL-17+ cells varied: when the highest num-
ber of IL-17+ cells in controls served as the cut-off, half the Crohn’s disease patients 
showed elevated levels of IL-17+ cells, as did 5 of 9 UC patients (original publica-
tion III, Figure 1). No significant difference in ileal IL-17 mRNA or IL-17+ cells 
appeared between study groups. The ratio of ileal IL-17+ cells to CD4+ cells dif-
fered, however, between these groups (P=0.027) and was higher in Crohn’s disease 
than in controls (P=0.016, Mann-Whitney U-test, original publication III, Figure 2). 
In agreement with Studies I and II, up-regulation of IL-17-related immunity oc-
curred in inactive Crohn’s disease, meaning that the classification separating ileal 
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from colonic Crohn’s disease may be clinically valid but immunologically arbitrary. 
As the children with UC showed no comparable ileal up-regulation of IL-17, locali-
zation of the disease is likely restricted.  
Natural and induced regulatory T cells need FOXP3 for their suppressor function 
(Chatila 2008). Increased intestinal FOXP3 has been reported in adult IBD patients 
(Maul et al. 2005), and was also seen in Study I. Study III reports increased intesti-
nal FOXP3 expression in pediatric UC similar to that reported in untreated pediatric 
Crohn’s disease patients (Reikvam et al. 2011). Colonic FOXP3 mRNA expression 
differed significantly between the groups and was higher both in Crohn’s disease 
and in UC than in reference subjects (original publication III, Figure 1). Colonic 
FOXP3+ cells differed between the three groups. Both Crohn’s disease and UC 
showed higher amounts of positive cells than in the controls (original publication III, 
Figure 1). Ileal FOXP3 mRNA or FOXP3+ cells showed no significant difference 
between the groups. In pediatric IBD, both in Crohn’s disease and UC, activation of 
colonic IL-17 and FOXP3 occur at protein and mRNA levels, indicating shared 
immunological characteristics. Unfortunately, we were unable to accomplish double 
staining for IL-17 and other markers such as FOXP3.  
FOXP3 blocks the ability of ROR-c to activate IL-17 immunity. IL-6 reverses 
this inhibition, but as FOXP3 mRNA is present in IL-6 treated cells, FOXP3 tran-
scription does not halt (Zhou et al. 2008). In Study III, the numbers of IL-6 tran-
scripts were up-regulated in the inflamed colonic mucosa both in Crohn’s disease 
and UC (original publication III, Figure 1), thus agreeing with the previous in vitro 
studies. In IBD, the pro-inflammatory environment including activation of IL-6 may 
explain simultaneous up-regulation of mucosal FOXP3 and IL-17. Elevated expres-
sion of bifunctional cytokine IL-22 transcripts was also associated with IL-17 re-
sponse in pediatric IBD (original publication III, Figure 1). The increased levels of 
IL-22 might not signify Th17 immunity, but instead may be produced by innate 
lymphoid cells, as seen in Crohn’s disease (Geremia et al. 2011). 
Maul et al. (2005) reported an increase in the number of regulatory 
CD4+CD25+FOXP3+	  cells in remission in peripheral blood but a decrease in active 
disease (Maul et al. 2005). As PBMC samples obtained from children in Study III 
were insufficient for suppression experiments, we investigated the percentage of 
Treg cells, evaluated as CD25brightCD4+ (Makita et al. 2004, Baecher-Allan et al. 
2005, Maul et al. 2005, Holmen et al. 2006), and the percentage of 
FOXP3+CD25highCD4+ cells. We found the percentages of both CD25highCD4+ and 
CD25highCD4+FOXP3+ cells to be higher in the children with IBD. 
CD25highCD4+FOXP3+ cells differed between the groups (P=0.014, Kruskall-Wallis) 
and to be significantly higher in Crohn’s disease than in the reference patients (Orig-
inal publication III, Figure 3). 
Children undergoing their first endoscopy and having newly diagnosed disease, 
showed no difference in any of the measured variables (Table 10) from children 
undergoing a follow-up endoscopy; the disease duration had no impact on results. 
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Medication and immunological differences showed no significant association. The 
controls were slightly younger than the patients, but no statistically significant dif-
ference existed between the groups. Thus, in Study III, the duration of disease had 
no impact on results. The sample size was, however, limited and allows no firm 
conclusions. 
As previously found in adult patients (Fujino et al. 2003), the up-regulation of 
IL-17 immunity existed also in pediatric IBD. This indicates that pediatric Crohn’s 
disease and UC share the same immunological background. Thus, clinical differ-
ences between pediatric Crohn’s disease and UC seem to be unrelated to IL-17 im-
munity.  
5.5 Intestinal immunity in celiac disease and type I diabetes  
Table 11. Immunological changes studied in celiac disease and T1D. 
 
Th1/Th2 type im-
munity IL-17 type immunity Regulatory T cells 
Potential celiac  
   disease - 
IL-17 mRNA ↔  
IL-17A secretion ↔ 
FOXP3 mRNA ↔ 
Celiac disease IFN-γ mRNA ↑ 
IL-17+ cells ↑  
IL-17 mRNA ↑  
IL-17A secretion ↔ 
FOXP3+ cells ↑  
FOXP3 mRNA ↑ 
GFD-celiac  
   disease  - IL-17 mRNA ↓ FOXP3 mRNA ↔ 
T1D IFN-γ mRNA ↔ 
IL-17+ cells ↔  
IL-17 mRNA ↔ 
FOXP3+ cells ↔  
FOXP3 mRNA ↔ 
T1D and celiac  
   disease - IL-17A secretion ↑ - 
 
Th1 and Th2 type of immunity in celiac disease  
Increased numbers of γδ T-cells and the up-regulation of the IFN-γ pathway charac-
terize the inflamed intestinal mucosa in celiac disease, a Th1-type disease (Kontakou 
et al. 1994, 1995, Nilsen et al. 1998, Westerholm-Ormio et al. 2002). Here, expres-
sion of IFN-γ transcripts was elevated in the children with celiac disease when com-
pared to levels in children with T1D or reference children (original publication IV, 
Figure 1). Dietary gliadin, however, may not be the only trigger to activate Th1 
response. Instead Th1 response is fundamentally associated with celiac disease: 
mucosal up-regulation of IFN-γ pathway remained elevated even one year after GFD 
(Lahdenpera et al. 2011).  
IL-17-related immunity in celiac disease and T1D 
Earlier studies have shown an association of mucosal IL-17 activation in untreated 
but not in GFD-treated celiac disease (Sapone et al. 2009, Monteleone et al. 2010). 
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In agreement is our demonstration of intestinal IL-17 up-regulation as a sign of vil-
lous atrophy and active celiac disease but as having no association with T1D (Table 
11). In children with untreated celiac disease, up-regulation of IL-17 immunity oc-
curred in the numbers of IL-17+ cells and in the amounts of IL-17 transcripts (origi-
nal publication IV, Figure 1). In children with untreated celiac disease, the number 
of IL-17+ cells correlated positively with their IL-17 mRNA expression levels 
(R=0.444; P=0.111, Spearman), whereas no such correlation appeared in the refer-
ence group (R=-0.247; P=0.555) or in children with T1D (R=-0.104; P=0.775). In 
Swedish patients, the mucosal IL-17 mRNA was higher in the children with untreat-
ed celiac disease than in the other groups (original publication IV, Figure 2). In addi-
tion, the duodenal samples of untreated celiac disease patients secreted spontaneous-
ly more IL-17A in vitro than did those of reference children: of the 23 celiac disease 
patients, secretion of IL-17 was above the detection limit in 8, but we found none in 
5 reference samples (original publication III, Figure 3).  
According to one recent study, the mucosa of untreated celiac disease patients 
presents gliadin-specific Th17 cells (Fernandez et al. 2011). As a sign of plasticity, 
these cells secrete pro-inflammatory and anti-inflammatory cytokines simultaneous-
ly, indicating events such as changes in the profile of secreted cytokines. Another 
recent study, however, showed that T cells reactive to deaminated gliadin secrete no 
IL-17 (Bodd et al. 2010). Our findings of the activation of IL-17 immunity only at a 
late stage of the disease may explain these discrepant reports. In agreement, Study 
IV showed the effect of GFD on intestinal IL-17 down-regulation (Table 11). Thus, 
IL-17 response associated with untreated celiac disease that is characterized by vil-
lous atrophy. During villous atrophy, up-regulation of IL-17A production can occur 
without marked expansion of Th17 cells.  
Similarly, our findings indicate that the wheat-gliadin-induced mucosal inflam-
mation seen in potential celiac disease does not include IL-17 immunity. TGA+ chil-
dren showed no up-regulation of IL-17 immunity, even though they show an elevat-
ed risk for celiac disease and can be categorized as having potential celiac disease. T 
cells reactive to deaminated gliadin secrete no IL-17 (Bodd et al. 2010), but gliadin-
specific Th17 cells do exist in the mucosa of untreated celiac disease patients (Fer-
nandez et al. 2011). These discrepant results could be explained by our findings of 
activated IL-17 immunity only at a late stage of the disease, because Th17 cells 
show plasticity by secreting both anti- and pro-inflammatory cytokines concurrently.  
An IL-1β and IL-6 cytokine environment supports the conversion of FOXP3 ex-
pressing Tregs to IL-17-secreting cells. In Study IV, the active celiac disease muco-
sa secreted both IL-1β and IL-6. Cultured small-intestinal specimens of patients with 
untreated celiac disease (with or without T1D) spontaneously secreted more IL-1β 
and IL-6 than did children with potential celiac disease or TGA- reference children 
(original publication IV, Figure 3). 
IL-17 immunity plays a dual role in tissue inflammation, which depends at least 
partly on the response of the target tissue to IL-17. The induction of IL-17 immunity 
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exacerbated the effector phase of autoimmune diabetes in a murine model of auto-
immune diabetes (Emamaullee et al. 2009), and in human islet cells IL-17 induced 
apoptotic mechanisms (Honkanen et al. 2010). In a rodent model, however, a com-
mensal bacteria strain mediated protection from autoimmune diabetes and caused 
induction of mucosal IL-17 immunity (Lau et al. 2011). In Study IV, the number of 
IL-17+ cells or transcripts exhibited no difference in T1D from those of the reference 
children.  
Bradshaw et al. (2009) showed that the number of IL-17-secreting cells from an-
ti-CD3-stimulated PBMCs was greater in long-term T1D (disease duration > 1 year, 
predominantly juvenile type of disease) than in controls, indicating that IL-17 relates 
to T1D. Between recent onset T1D (disease duration <1 year, predominantly adult 
onset) and controls, however, we found no significant difference. In T1D, up-
regulation of IL-17 immunity has been evident in peripheral blood (Honkanen et al. 
2010).  
Similarly to Crohn’s disease, IL-23 mRNA seemed to be up-regulated in celiac 
disease, but surprisingly, IL-23R mRNA was slightly down-regulated in celiac dis-
ease and T1D when compared to controls. The ratio of IL-23 mRNA to IL-23R 
mRNA showed a statistically significant elevation in celiac disease (Figure 6). This 
finding of elevated ratio of IL-23 to IL-23R needs further study for evaluation. 
 
 
Figure 6. Levels of IL-23 and IL-23 transcripts in T1D and celiac disease. 
Due to the difference in RNA isolation steps between the Finnish and Swedish 
samples, between series of samples, the levels of transcripts varied. In Finnish sam-
ples, RNA was isolated from samples embedded in OCT matrix, and IL-17A mRNA 
fell below the detection limit in 10 of 13 children with T1D, in 8 of 9 reference chil-
dren, and in 2 of 14 children with untreated celiac disease. In Swedish samples, IL-
17A was undetectable in only 2 of 17 reference children and in 1 of 8 children with 
potential celiac disease. The Swedish reference children were younger than their 
celiac disease patients, but no correlation appeared between IL-17 mRNA expres-
sion and age (r=0.193; P=0.16). 
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In Caco2-cells, IL-17-induced apoptosis  
IL-17 plays a role in the induction of epithelial cell apoptosis and villous atrophy 
(Mazzarella et al. 2008). Thus, to study induction of apoptosis, we treated the epithe-
lial cell line Caco-2 with IL-17. As TNF-α is apoptotic for epithelial cells (Gitter et 
al. 2000), we examined the apoptotic effects of IL-17 on Caco2 cells in vitro, alone, 
or in combination with TNF-α. Caco2 cells show high expression of IL-17RA 
mRNA transcripts. Furthermore, incubation with IL-17 enhanced the transcription of 
the anti-apoptotic gene bcl-2 but showed a slight decrease in the expression of apop-
totic-signaling gene BAX, which is active in the apoptosis (original publication IV, 
Figure 4). Thus, IL-17 may not contribute to the apoptosis of enterocytes, but in-
stead it possibly activates protective anti-apoptotic mechanisms in ECs. In tissue 
inflammation, IL-17 immunity seems to play a dual role that may depend at least 
partly on the target tissue’s response to IL-17.  
In a murine model of autoimmune diabetes, during the effector phase of the dis-
ease the induction of IL-17 immunity exacerbated diabetes, and in human islet cells, 
IL-17 caused apoptosis (Emamaullee et al. 2009, Honkanen et al. 2010). A recent 
study showed that in a rodent model, a commensal bacterial strain protective against 
autoimmune diabetes caused induction of mucosal IL-17 immunity (Lau et al. 
2011). As also suggested by others, our results support the view that up-regulation 
of intestinal IL-17 immunity is linked with the mechanisms of protection from tissue 
damage in the inflamed mucosa (Blaschitz, Raffatellu 2010), which could thus ex-
plain the beneficial effects of mucosal IL-17 up-regulation in autoimmune diabetes. 
In children with T1D, evidence exists of enhanced activation of IL-17 immunity in 
peripheral blood T cells (Honkanen et al. 2010). We, however, found no evidence of 
the up-regulation of small intestinal IL-17 immunity in children with T1D but with-
out celiac disease. 
An elevated level of IL-17 immunity existed only in children with both T1D and 
celiac disease. T1D patients with celiac disease spontaneously released significantly 
more intestinal IL-17 in vitro (P=0.0049, Kruskall-Wallis, Figure 7). When com-
pared to patients with celiac disease alone or to reference children, they secreted an 
elevated amount of IL-17A (P=0.009 and 0.015, Fischer´s exact test; the detection 
limit served as the cut-off line). Thus, under certain conditions, T1D possibly induc-
es IL-17 production, such as when high-grade mucosal inflammation associates with 
villous atrophy. Interestingly, the Langerhans islets from a newly diagnosed T1D 
patient showed elevation in IL-17A transcripts when compared to that of non-
diabetic individuals (Arif et al. 2011). Possibly IL-17+ cells infiltrate to the islets 
instead of to the intestine. Our samples were from the small intestine, but in 
nonobese diabetic mice, up-regulation of IL-17 immunity has occurred in the colon 
(Alam et al. 2010). Up-regulation of IL-17 contributes to the villous atrophy related 
to untreated celiac disease.  
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Figure 7. Biopsy specimens from children with both celiac disease and T1D secreted higher 
amounts of IL-17, also when compared to the children with only celiac disease (P=0.0156, Mann-
Whitney U-test). 
As IL-17 did not promote apoptotic mechanisms in the CaCo-2 epithelial cell 
line, it may not act as a direct trigger of villous atrophy and tissue destruction. IL-17 
up-regulation implied active celiac disease; its role as a predictive biomarker of 
villous atrophy, and the need for small intestinal biopsy in TGA+ subjects require 
further study. 
Intestinal FOXP3 in celiac disease and type 1 diabetes  
Studies suggest that the number of FOXP3+ cells is increased in celiac disease and 
especially in those with coexisting T1D (Vorobjova et al. 2008). This is in agree-
ment with other findings implying that children with celiac disease or T1D in com-
bination with celiac disease had higher FOXP3 mRNA expression levels in BPMC 
than did healthy or children with T1D (Kivling et al. 2008). In Study IV, in the Finn-
ish children the number of FOXP3+ cells and amount of FOXP3 mRNA differed 
significantly between the groups. When compared to T1D and reference children, an 
elevated number of FOXP3+ cells and higher FOXP3 mRNA levels appeared in 
untreated celiac disease. In the Swedish children, however, the mucosal FOXP3 
mRNA expression differed between the study groups, being higher in the children 
with untreated celiac disease than in GFD-treated children, in children with potential 
celiac disease, or in TGA- children. Between children with treated celiac disease and 
TGA- reference children, no difference existed in the FOXP3 mRNA expression 
levels (original publication IV, Figure 1).  
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In children with untreated celiac disease, we found up-regulation of intestinal 
FOXP3 to associate with enhanced IL-17 immunity: IL-17 mRNA correlated posi-
tively with FOXP3 mRNA in untreated celiac disease (r=0.60, P=0.03 Spearman). 
Studies have suggested that FOXP3-expressing Tregs show plasticity, and in in-
flamed tissue, may develop into Th17 cells (Ayyoub et al. 2009, Komatsu et al. 
2009, Zhou et al. 2009). Similar to IL-17 immunity, the activation of intestinal 
FOXP3 seems to occur only in the late phase of disease progression, and potential 
celiac disease did not exhibit up-regulation of FOXP3. GFD treatment, however, 
normalized the expression of both FOXP3 and IL-17 (Figure 8). 
 
 
 
Figure 8. Patogenesis of celiac disease. Gluten-free diet (GFD). 
 
The mucosal cytokine environment in celiac disease supports IL-17 differentia-
tion, but may cause impaired suppressive function of FOXP3-expressing cells (Beri-
ou et al. 2009). A recent study suggested that Th17 cell clones might also change 
their phenotype when RORc is down-regulated and FOXP3 up-regulated upon re-
peated TCR engagement (Ye et al. 2011). This kind of plasticity may explain the 
low RORc mRNA expression in association with IL-17 and FOXP3 expression that 
was demonstrated in the mucosa of untreated celiac disease. In Study IV, the expres-
sion of RORc mRNA showed no difference between the study groups (original pub-
lication IV, Figure 2), nor did RORc mRNA correlate with IL-17 mRNA (r=-0.24, 
P=n.s., Spearman). 
During pathogenesis of T1D, autoreactive T cells destroy insulin-secreting pan-
creatic islet β-cells, causing insulin deficiency and elevated plasma glucose levels 
(Atkinson, Maclaren 1994). According to other reports, increased numbers of HLA 
class II-, CD25-, MadCAM-1-, IL-1-, and IL-4-positive cells signal promoted small 
intestinal immune activation in T1D (Westerholm-Ormio et al. 2003, Tiittanen et al. 
2008, Auricchio et al. 2004), thus suggesting therefore intestinal inflammation as 
part of the disease pathogenesis (Vaarala 2008a, Vaarala et al. 2008b). Based on 
animal studies, alterations in the gut immune system such as increased permeability 
and enteropathy seem to be key regulators of autoimmune insulitis and of develop-
ment of T1D (Graham et al. 2004, Neu et al. 2005). In T1D, the number of intestinal 
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FOXP3+ Treg cells is reduced because of their defective differentiation in the intes-
tine (Badami et al. 2011). A previous study from our group showed no infiltration of 
FOXP3-expressing cells in the small intestinal mucosa in T1D (Tiittanen et al. 
2008), and Study IV confirms this, because no difference in the number of FOXP3+ 
cells or transcripts emerged between T1D children and the reference children (origi-
nal publication IV, Figure 1). 
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6 Conclusions 
Changes in immunological balance play a crucial role in inflammatory bowel dis-
ease, in celiac disease, and in T1D. During recent years, the new types of Th cells 
detected have been of great importance. This thesis has focused on the IL-17 type of 
immunity and on the balance between Tregs and Th17 cells.  
In adult patients, IL-17 immunity plays a fundamental role in active and inactive 
Crohn’s disease. Activation of the IL-23/IL-17 axis is associated with the etiology of 
Crohn’s disease, and by causing increased sensitivity of the epithelium to microbial 
LPS, it may also be the basis for the relapsing nature of the disease. Immunomodula-
tory treatment such as with TNF-α-blocking agents ameliorated the balance between 
intestinal IL-17+ T-effector and regulatory cells, despite the fact that, even after 
TNF-α blocking treatment, intestinal IL-17 upregulation persisted. 
In pediatric IBD patients, studies of the role of IL-17 immunity are lacking, alt-
hough the need for pediatric studies is widely acknowledged among pediatricians. In 
our study, no difference existed between pediatric Crohn’s disease and UC, because 
the inflamed mucosa exhibited IL-17 upregulation in both diseases.  
In celiac disease, upregulation of IL-17 immunity has a link to the villous atro-
phy seen in the late stage of the disease, but not to early phases preceding atrophy. 
After GFD, the level of IL-17 type immunity and the structure of the intestine are 
restored. In TID, no mucosal IL-17 up-regulation existed. As IL-17 showed no pro-
motive effect on the apoptotic mechanism in the Caco-2 epithelial cell line, IL-17, 
however, may not be the initial step causing villous atrophy and tissue damage.  
To conclude: based on these studies, the IL-17 type of immunity and increased 
levels of regulatory T cells are present in IBD and celiac disease when the structure 
of the intestine is disrupted, and in IBD also when the mucosa has healed. Anti-
TNF- α-blocking is incapable of reversing completely the immunological changes in 
Crohn’s disease, but it seems to play a role in the balance between effector and regu-
latory T cells. IL-17 immunity was not upregulated in T1D, in which tissue destruc-
tion of the intestine is absent. IL-17 immunity thus appears to be one of the causes 
of tissue damage in IBD and celiac disease. It, therefore, seems, based on this thesis 
and on the current literature, that IL-17, functioning with IFN-γ, either exacerbates 
or promotes the tissue destruction seen in Crohn’s disease and celiac disease. By 
itself, IL-17 may, however, play a protective role. 
Due to methodological difficulties in this thesis, IL-17-positive cells could not be 
specified in detail, and we lack full understanding of these cells, although their up-
regulation in IBD and celiac disease is evident. Detailed characterization of IL-17 
type immunity would be a necessary object for future studies. 
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